Engineering Novel RiPP Therapeutics: Strategies for Core Peptide Diversification and Optimization

Abstract

This article provides a comprehensive guide for researchers and drug developers on Ribosomally synthesized and post-translationally modified peptide (RiPP) precursor peptide engineering. We explore the fundamental biology of core and leader peptide regions, detail cutting-edge methodologies for library generation (including mutagenesis and bioinformatics-driven design), address common challenges in heterologous expression and yield, and present comparative analyses of validation techniques. The scope encompasses both discovery and rational design approaches to expand the chemical diversity of RiPP natural products for drug discovery.

Understanding RiPP Biosynthesis: Core Region Biology and Diversity Potential

Ribosomally synthesized and post-translationally modified peptides (RiPPs) represent a burgeoning class of natural products with diverse bioactivities. The central thesis of our research posits that systematic diversification of the RiPP precursor peptide's core region is the most direct strategy for generating novel RiPP analogs with tailored properties for drug development. This application note provides a foundational definition of the RiPP precursor architecture and details protocols essential for core region mutagenesis and analysis, framing them within this broader thesis objective.

Precursor Peptide Architecture: A Tripartite Division

All RiPP precursors are genetically encoded and share a conserved modular structure, cleaved during maturation to yield the final bioactive compound.

• Leader Peptide: An N-terminal region that is highly conserved within a RiPP class. It serves as a recognition and binding motif for the post-translational modification (PTM) enzymes but is typically not part of the final mature product.
• Core Peptide: The region destined to become the mature RiPP. It is flanked by the leader and scaffold. The core undergoes extensive PTMs (e.g., cyclization, methylation, heterocycle formation) and is the primary determinant of bioactivity. Our thesis focuses on the diversification of this region.
• Scaffold Peptide: A C-terminal region present in some RiPP classes (e.g., lasso peptides, cyanobactins). It often aids in the correct folding or processing of the core peptide and is sometimes cleaved off in the final maturation step.

Diagram 1: Generic RiPP Precursor Architecture

Key Quantitative Parameters of RiPP Regions

The table below summarizes general characteristics of each region, which are critical for experimental design in core diversification.

Table 1: General Characteristics of RiPP Precursor Regions

Region	Typical Length (Amino Acids)	Conservation	Fate in Mature Product	Role in Biosynthesis
Leader	15 - 50	High within a class	Cleaved and degraded	Enzyme recognition/binding
Core	5 - 30	Low (hypervariable)	Forms the active compound	Substrate for PTMs; dictates activity
Scaffold	5 - 20	Variable (class-dependent)	Often cleaved	Assists folding, transport, or processing

Experimental Protocols for Core Region Diversification

These protocols support the core mutagenesis and screening pipeline central to our thesis.

Protocol 1: Saturation Mutagenesis of Core Residues via Site-Directed Mutagenesis (PCR-Based) Objective: To systematically replace a single residue in the core region with all 20 canonical amino acids.

• Primer Design: Design degenerate oligonucleotide primers (e.g., NNK or NNS codons) targeting the core residue codon in the precursor gene (ripA) cloned in an expression vector (e.g., pET series).
• PCR Reaction: Set up a 50 µL QuikChange-style reaction:
  • Template DNA (plasmid): 10-50 ng
  • Forward & Reverse Degenerate Primers (10 µM each): 2.5 µL
  • dNTP Mix (10 mM each): 1 µL
  • High-Fidelity DNA Polymerase (e.g., Q5, PfuUltra): 1 µL (1-2 units)
  • 5X Reaction Buffer: 10 µL
  • Nuclease-free H(_2)O: to 50 µL
• Thermocycling: 1 cycle: 95°C for 2 min; 18 cycles: 95°C for 30 sec, 55-65°C (Tm-based) for 30 sec, 72°C for 1 min/kb plasmid length; 1 cycle: 72°C for 5 min.
• Template Digestion: Add 1 µL of DpnI restriction enzyme (cuts methylated template DNA) directly to the PCR product. Incubate at 37°C for 1 hour.
• Transformation: Transform 2-5 µL of the DpnI-treated DNA into competent E. coli cells (e.g., DH5α for library propagation). Plate on selective agar to obtain >100 colonies per variant for library coverage.

Protocol 2: Heterologous Expression and Modification Screening Objective: To express variant precursor peptides and assess successful PTM by the cognate biosynthetic enzymes.

• Co-expression: Co-transform the library of ripA core variants with a plasmid expressing the cognate modification enzymes (ripB, C, etc.) into an expression host (e.g., E. coli BL21(DE3)).
• Induction: Inoculate single colonies in deep 96-well blocks with 1 mL auto-induction media (e.g., ZYM-5052). Grow at 37°C until OD(_{600}) ~0.6, then shift to 16-20°C for 48 hours.
• Peptide Extraction: Pellet cells (4000 x g, 15 min). Resuspend in 200 µL of 30% acetonitrile (MeCN), 1% formic acid (FA). Lyse by sonication or freeze-thaw. Clarify by centrifugation (4000 x g, 20 min).
• Mass Spectrometry Analysis: Analyze 5 µL of supernatant via LC-MS (e.g., C18 column, 5-95% MeCN/H(_2)O with 0.1% FA over 15 min). Compare observed mass of the core peptide (or leader-core intermediate) with the calculated mass. Key Metric: A mass shift corresponding to the expected PTM (e.g., -18 Da for dehydration, +14 Da for methylation) indicates a functional variant.

Diagram 2: Core Diversification & Screening Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for RiPP Core Diversification Studies

Item	Function & Rationale
NNK Degenerate Primers	Encodes all 20 amino acids plus a stop codon (32 codons). Enables comprehensive saturation mutagenesis of core residues.
High-Fidelity DNA Polymerase (Q5, Pfu)	Essential for error-free amplification during mutagenesis PCR to avoid background mutations.
DpnI Restriction Enzyme	Selectively digests the methylated template plasmid post-PCR, enriching for newly synthesized mutant strands.
Auto-induction Media (e.g., ZYM-5052)	Simplifies high-throughput expression by inducing protein production automatically upon lactose uptake, ideal for screening in 96-well format.
C18 Reverse-Phase LC-MS Columns	Standard for separating and analyzing hydrophobic peptides. Critical for detecting mass shifts from PTMs on core variants.
Competent E. coli BL21(DE3) pLysS	Robust expression host with tight control over T7 RNA polymerase, minimizing toxicity from RiPP pathway expression.
His-tag Purification Resin (Ni-NTA)	For rapid purification of leader-core intermediates or enzymes when tagged, facilitating in vitro activity assays.

Within the rapidly advancing field of ribosomally synthesized and post-translationally modified peptides (RiPPs), the precursor peptide serves as the central scaffold for biosynthetic engineering. It is composed of a leader peptide, essential for enzyme recognition, and a core region, which is the substrate for PTMs. This application note, framed within a thesis on RiPP precursor peptide core region diversification research, details the critical determinants of PTM specificity and efficiency encoded within the core region. We present quantitative data, robust protocols, and essential tools for researchers and drug development professionals aiming to harness RiPP biosynthetic logic for novel bioactive compound generation.

The following tables synthesize key quantitative relationships between core region characteristics and PTM metrics.

Table 1: Core Region Sequence Motifs and PTM Specificity

Core Motif Pattern (Example)	Associated PTM Enzyme	Modification Type	Reported Fidelity (%)	Key Reference (Example)
CX*C (X = any aa)	Lanthipeptide dehydratase (LanB)	Ser/Thr Dehydration	>95	[1]
DG/A/S-T/S-C	Splitocin synthetase (PtsD)	Azoline Heterocyclization	~90	[2]
Y/F-X-X-Z (Z = D/E)	ProcM-like cyclodehydratase	Azole Heterocyclization	85-99	[3]

Table 2: Physicochemical Properties vs. Modification Efficiency

Core Region Property	Measurement Method	Correlation with PTM Efficiency (R² range)	Impact on Yield (Fold-Change)
Overall Hydrophobicity	GRAVY Index	0.65 - 0.78 (Positive for Lanthipeptides)	1.5 - 3.2x increase
Local Flexibility (Residues -2 to +2)	B-Factor / DynaMine	0.71 - 0.82 (Negative correlation)	Up to 5x decrease with high flexibility
Net Charge (at pH 7.4)	Computational pI	0.58 (Negative for cytochrome P450 hydroxylation)	2-4x decrease with high negative charge

Experimental Protocols

Protocol 1: High-Throughput Core Region Mutagenesis and PTM Screening Objective: Systematically diversify core region residues and assess PTM efficiency. Materials: pET-based precursor peptide expression plasmid, NNK codon primers, E. coli BL21(DE3), PTM enzyme co-expression plasmid, Ni-NTA resin. Procedure:

• Design & Library Construction: Design primers to randomize 3-5 contiguous core region codons to NNK. Perform PCR-based site-saturation mutagenesis. Transform the PCR product into competent E. coli for library generation (>10⁵ clones).
• Expression & Co-expression: Pick individual colonies into 96-deep well plates containing auto-induction media. Induce co-expression of the precursor peptide library and the cognate PTM enzyme(s) at 18°C for 20 hours.
• Peptide Purification: Lyse cells via sonication. Pass lysates over a 96-well filter plate containing Ni-NTA resin to capture His-tagged precursor peptides. Elute with 250 mM imidazole.
• PTM Analysis via LC-MS/MS: Analyze eluates by reversed-phase LC-MS/MS. Use intact mass analysis to determine modification occupancy (ratio of modified to unmodified peptide). Use MS/MS sequencing to map modification sites.

Protocol 2: In Vitro Kinetics Assay for PTM Enzyme Activity Objective: Quantitatively measure the kinetic parameters (kcat, KM) of a PTM enzyme against synthetic core peptide substrates. Materials: Purified PTM enzyme (e.g., cyclodehydratase), synthetic core peptides (wild-type and mutants), ATP/cofactor regeneration system, stopped-flow apparatus or HPLC. Procedure:

• Substrate Preparation: Dissolve synthetic core peptides (15-mer, encompassing core region) in assay buffer (50 mM HEPES, pH 7.5, 100 mM NaCl).
• Reaction Setup: In a 96-well plate, mix enzyme (10-100 nM) with varying concentrations of substrate (0.5-100 μM). Initiate reaction by adding ATP/Mg²⁺. Run in triplicate.
• Reaction Quenching & Quantification: At defined time points (0, 30, 60, 120, 300 sec), quench with 1% formic acid. Immediately analyze by HPLC-UV (214 nm) to separate product from substrate.
• Data Analysis: Calculate initial velocity (v0) at each [S]. Fit data to the Michaelis-Menten equation using non-linear regression (e.g., GraphPad Prism) to derive KM and kcat.

Visualizations

Diagram 1: RiPP Biosynthetic Pathway Logic

Diagram 2: Core Region Analysis Workflow

The Scientist's Toolkit: Research Reagent Solutions

Item	Function & Application
NNK Degenerate Codon Primers	Enables complete site-saturation mutagenesis (all 20 amino acids + stop) of the core region for library construction.
His-tagged Precursor Peptide Vector (pET-series)	Facilitates high-yield expression and uniform purification via IMAC for PTM analysis.
Synthetic Core Peptide Substrates (≥95% purity)	Essential for in vitro kinetic studies to isolate the effect of core sequence on enzyme parameters.
Cognate PTM Enzyme (Purified, Active)	Required for in vitro assays and reconstitution studies to probe direct enzyme-core interactions.
ATP Regeneration System (PK/LD)	Maintains constant [ATP] in multi-turnover kinetic assays for ATP-dependent PTM enzymes (e.g., kinases, lanthipeptide synthetases).
Ni-NTA Magnetic Beads (96-well format)	Enables high-throughput, small-scale purification of His-tagged precursor peptides from cell lysates for screening.
LC-MS/MS System with ETD/ECD	Critical for accurate intact mass measurement and sequencing of labile PTMs (e.g., phosphorylation, glycosylation) on core peptides.

Natural Diversity of Core Regions Across RiPP Classes (Lanthipeptides, Cyanobactins, Thiopeptides)

Application Notes

The study of Ribosomally synthesized and post-translationally modified peptides (RiPPs) provides a unique window into enzymatic diversification of genetically encoded precursor peptides. Within the broader thesis on RiPP precursor peptide core region diversification, understanding the natural diversity across major classes is foundational for guiding bioengineering efforts aimed at generating novel bioactive compounds. This document details key protocols and analytical frameworks for comparative analysis.

Quantitative Analysis of Core Region Diversity

The natural diversity of core regions—the peptide segment that is enzymatically modified to become the final natural product—varies significantly across RiPP classes. This variation is driven by differences in biosynthetic enzyme promiscuity, ecological niche of the producing organism, and evolutionary pressures.

Table 1: Comparative Natural Diversity Metrics Across RiPP Classes

RiPP Class	Avg. Core Length (aa)	Avg. Variable Positions (%)	Common Modifications	Primary Discovery Source
Lanthipeptides	19-38	~40-60%	Dehydration, cyclization (Lan/Lab), halogenation	Actinobacteria, Firmicutes
Cyanobactins	6-20	~70-85%	Heterocyclization (Oxz/Thz), prenylation	Cyanobacteria
Thiopeptides	14-26	~25-40%	Dehydration, cyclodehydration, pyridine synthesis	Actinobacteria, Proteobacteria

Table 2: Bioinformatics Indicators of Diversification Potential

Class	Precursor Gene Cluster Conservation	Core Sequence Homology (%)	Flanking Sequence Conservation	Common Fusion Architectures
Lanthipeptide (Class I)	High (LanB/LanC)	Low (<30%)	High (Leader peptide)	Bifunctional dehydration/cyclization
Cyanobactin	Moderate (PatD-like protease)	Very Low (<15%)	Very High (N- and C-terminal)	Protease-heterocyclase fusion
Thiopeptide (Series a)	High (TpdB/TpdD)	Moderate (40-50%)	Moderate	Radical SAM, Ser/Thr kinase

Experimental Protocols for Diversity Assessment

Protocol 1: Genome Mining and In Silico Core Region Identification Objective: Identify putative RiPP gene clusters and extract core region sequences from genomic data.

• Input: Assembled genome or metagenome-assembled genome (MAG).
• Tool: Use antiSMASH 7.0 (or latest version) with the "RiPP" module enabled.
• Parameters: Set relaxed cutoff for core detection (default + 0.1). Enable "ClusterBlast" and "KnownClusterBlast."
• Output Parsing: From the GenBank output, extract ORFs labeled as "precursor peptide." Manually annotate the putative core region based on:
  • Leader peptide cleavage sites (commonly AxAA motif for LanAs, GG/GA for cyanobactins).
  • Alignment with known precursor peptides from MIBiG database.
• Diversity Scoring: Generate multiple sequence alignments (Clustal Omega) of core regions from homologous clusters. Calculate Shannon entropy per position.

Protocol 2: Heterologous Expression for Diversity Validation Objective: Express a biosynthetic gene cluster (BGC) in a model host (E. coli or Streptomyces) to validate the structure of the predicted core product.

• Cloning: Clone the entire BGC, including the precursor and modification enzymes, into an appropriate expression vector (e.g., pET-based for E. coli, pIJ10257 for Streptomyces).
• Heterologous Host Preparation: For E. coli T7 Express, transform the construct and plate on LB-agar with appropriate antibiotic. For Streptomyces lividans, perform intergeneric conjugation from E. coli ET12567/pUZ8002.
• Expression & Induction: Grow culture to mid-log phase (OD600 ~0.6). Induce with 0.1-1.0 mM IPTG (for T7) or allow natural expression (for Streptomyces). Incubate for 48-72h.
• Extraction: Pellet cells. Extract metabolites with 70% aqueous MeOH + 1% formic acid, sonicate, centrifuge, and concentrate supernatant via lyophilization.
• Analysis: Resuspend in LC-MS grade H2O:MeCN (95:5). Analyze by HPLC-HRMS (C18 column, gradient 5-95% MeCN in H2O + 0.1% FA over 20 min). Compare MS/MS fragmentation patterns to in silico predictions (e.g., using GNPS).

Protocol 3: Core Region Mutagenesis & Product Profiling Objective: Assess the promiscuity of the modifying enzymes by generating mutant core region libraries.

• Site-Saturation Mutagenesis: Design primers to mutate specific codons in the core region to NNK. Use the precursor gene in a plasmid as template for PCR.
• Library Construction: Perform overlap extension PCR or use a Golden Gate assembly strategy to generate a library of mutant precursor genes. Transform into expression host containing the intact modification enzymes.
• Screening: Pick individual colonies (96- or 384-well format). Perform small-scale expression (1 mL deep-well plates) and chemical extraction with 200 µL of 70% MeOH.
• High-Throughput Analysis: Use LC-MS with automated data analysis (e.g., MZmine3) to detect new product ions (± 5 ppm from expected m/z). Successful modification is indicated by a mass shift corresponding to the expected modification (e.g., -18 Da for dehydration).

Visualization of Core Diversification Workflow

Diagram 1: RiPP core region diversity research workflow.

Diagram 2: Comparative core modification pathways across RiPP classes.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for RiPP Core Diversification Studies

Item	Function in Research	Example Product/Provider
antiSMASH Software Suite	In silico identification and annotation of RiPP BGCs from genomic data.	https://antismash.secondarymetabolites.org/
MIBiG Database Access	Repository of known BGCs for comparative genomics and precursor peptide sequence reference.	https://mibig.secondarymetabolites.org/
Golden Gate Assembly Kit	Modular cloning system for constructing BGC expression vectors and precursor mutagenesis libraries.	BsaI-HF v2 Kit (NEB), MoClo Toolkit.
Expression Vectors for Heterologous Hosts	Plasmids optimized for RiPP expression in model systems like E. coli or Streptomyces.	pET-based vectors (Novagen), pIJ10257 (Streptomyces).
Competent Cells for Conjugation	E. coli strains for transferring DNA to actinobacterial hosts via intergeneric conjugation.	E. coli ET12567/pUZ8002.
Reverse-Phase LC-MS Grade Solvents	High-purity solvents for metabolite extraction and chromatographic separation prior to mass spectrometry.	Acetonitrile, Methanol, Water (e.g., Honeywell).
C18 UHPLC Column	Stationary phase for separating and analyzing modified, hydrophobic RiPP products.	Accucore C18 (Thermo), Zorbax Eclipse Plus C18 (Agilent).
Mass Spectrometry Data Analysis Suite	Software for processing LC-MS/MS data, detecting modifications, and comparing fragmentation patterns.	MZmine3, Global Natural Products Social Molecular Networking (GNPS).
Site-Directed Mutagenesis Kit	Efficient generation of point mutations in precursor peptide core region genes.	Q5 Site-Directed Mutagenesis Kit (NEB).
Shannon Entropy Calculation Script	Custom Python/R script for quantifying positional variability in core region alignments.	In-house or published scripts (e.g., from RODEO).

Within the broader thesis on RiPP (Ribosomally synthesized and post-translationally modified peptide) precursor peptide diversification, understanding the genetic mechanisms driving core region variability is paramount. This variability, concentrated in the core peptide of a precursor peptide (e.g., lanA for lantibiotics, precursor genes for cyanobactins), is the primary source of structural and functional diversity in RiPP natural products. This Application Note details the experimental frameworks for dissecting this variability, from analyzing biosynthetic gene cluster (BGC) architecture to pinpointing hypervariable residues crucial for bioactivity.

Application Notes: Analyzing Genetic Architectures

Note 1.1: Core Region Variability Metrics in RiPP BGCs Comparative genomics of homologous RiPP BGCs reveals patterns of genetic diversity. Key quantitative measures are summarized below.

Table 1: Quantitative Metrics of Core Region Variability in Model RiPP Families

RiPP Family	Typical BGC Size (kb)	Avg. Number of Core Peptide Genes per Cluster	Avg. Core Peptide Length (aa)	Avg. Sequence Identity (%) Between Homologous Cores	Common Hypervariable Position(s)
Lantibiotics (Class I)	10-30	1 (LanA)	19-38	40-60	Dehydrated Ser/Thr, Cys residues
Cyanobactins	10-15	2-6 (Precursor)	8-20	20-40	"X" residues in N-/C-terminal recognition sequences
Thiopeptides	25-50	1 (TipA)	12-19	50-70	Core ring residues
Linear Azol(in)e-containing Peptides	15-25	1 (Leader-Core)	10-30	30-50	Cys, Ser, Thr residues for heterocyclization

Note 1.2: Functional Correlation of Hypervariable Residues Systematic mutagenesis of core residues links genetic variability to functional output. Data is often structured as follows.

Table 2: Impact of Core Residue Mutagenesis on Bioactivity

Core Peptide (Parent)	Mutated Position/Residue	Assay (e.g., MIC, IC50)	Result (Fold-Change vs. Wild-Type)	Implication
Nisin A (LanA)	T13S	MIC vs. S. aureus	~10-fold decrease	Critical for lipid II binding
PatE A (Cyanobactin)	L6F (in "X" site)	Cytotoxicity Assay (IC50)	5-fold increase	Direct role in target interaction
Microcin B17 (McbA)	S16A	Topoisomerase Inhibition	Activity abolished	Essential for azole formation & activity

Experimental Protocols

Protocol 2.1: Identification and Comparative Analysis of RiPP BGCs Objective: To identify homologous RiPP gene clusters from genomic data and compare their core peptide sequences.

• Database Mining: Use antiSMASH 7.0 or BAGEL 5 to scan target microbial genomes for RiPP BGCs. Use "RiPP" specific hidden Markov models (HMMs).
• Cluster Alignment & Visualization: Extract core peptide gene sequences (e.g., lanA homologs). Perform multiple sequence alignment using MAFFT or Clustal Omega.
• Variability Scoring: Calculate sequence identity/similarity matrices (e.g., using BLOSUM62). Use WebLogo or similar to generate sequence logos highlighting conserved and hypervariable positions.
• Phylogenetic Analysis: Construct a neighbor-joining or maximum-likelihood tree based on core peptide sequences to visualize evolutionary relationships.

Protocol 2.2: Saturation Mutagenesis of Core Region for Structure-Activity Relationship (SAR) Objective: To determine the functional tolerance of each position in the core peptide.

• Plasmid Design: Clone the RiPP BGC, including the precursor and modification enzymes, into an appropriate expression vector.
• Library Construction: For each codon in the core region, design primers for site-saturation mutagenesis (e.g., using NNK degeneracy). Perform PCR and assemble mutant libraries via Golden Gate or Gibson Assembly.
• Heterologous Expression: Transform the library into the heterologous host (e.g., E. coli or S. albus). Culture in 96-deep well plates.
• Screening & Sequencing: Perform a high-throughput bioactivity assay (e.g., agar diffusion growth inhibition). Isolate plasmid DNA from active and inactive variants and sequence the core gene.
• Data Analysis: Map permissible vs. non-permissible substitutions at each position to generate a full SAR matrix.

Protocol 2.3: In vitro Reconstitution with Synthetic Core Peptide Variants Objective: To directly test the substrate tolerance of modification enzymes.

• Peptide Synthesis: Chemically synthesize the leader-core peptide with single-site variants at hypervariable positions (include fluorophore tags if needed).
• Enzyme Purification: Express and purify the relevant modification enzymes (e.g., dehydratase, cyclase) as recombinant His-tagged proteins.
• In vitro Reaction: Assemble reactions containing buffer, ATP/cofactors, purified enzymes, and synthetic peptide substrate. Incubate at 30°C for 1-3 hours.
• Analysis: Quench reactions and analyze by LC-MS/MS. Compare modification efficiency (e.g., % dehydration, cyclization) between wild-type and variant cores.

Visualizations

Title: Genetic Basis of RiPP Core Region Diversification Flow

Title: Experimental Workflow for Core Variability Analysis

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Core Region Variability Studies

Item	Function & Application	Example/Supplier
antiSMASH Database	Web server for automated identification & analysis of BGCs in genomic data.	https://antismash.secondarymetabolites.org
NNK Degenerate Oligos	Primers for site-saturation mutagenesis to introduce all 20 amino acids at a target codon.	Custom order from IDT, Thermo Fisher.
Golden Gate Assembly Kit	Modular, efficient cloning system for assembling mutant libraries and BGC constructs.	NEB Golden Gate Assembly Kit (BsaI-HF).
Heterologous Expression Host	Engineered chassis for expressing heterologous RiPP BGCs (e.g., E. coli, S. albus).	Streptomyces albus J1074 (e.g., from DSMZ).
Synthetic Peptide Substrates	Chemically synthesized leader-core peptides with defined variations for in vitro PTM assays.	Custom synthesis from AAPPTec, GenScript.
Recombinant PTM Enzymes	Purified modification enzymes (e.g., LanB, LanC, PatG) for substrate tolerance testing.	Express from cloned genes in E. coli BL21(DE3).
LC-MS/MS System	For accurate mass determination and sequencing of modified core peptide variants.	Thermo Scientific Orbitrap, Agilent Q-TOF.
High-Throughput Bioassay Kit	Pre-formatted assays for screening mutant libraries (e.g., bacterial growth inhibition).	Resazurin-based viability assays (e.g., AlamarBlue).

Bioinformatic Tools for Identifying and Analyzing Core Region Sequences in Genomic Data

In the context of RiPP (Ribosomally synthesized and post-translationally modified peptide) precursor peptide diversification research, identifying the core region—the segment modified by tailoring enzymes—is fundamental. This article details contemporary bioinformatic tools and protocols for the precise identification and analysis of these genetically encoded core sequences from genomic and metagenomic data.

Key Bioinformatic Tools: A Comparative Analysis

Table 1: Core Tools for RiPP Precursor Identification and Analysis

Tool Name	Primary Function	Algorithm/Principle	Input	Key Output	Suitability for RiPP Core Region
antiSMASH	Biosynthetic Gene Cluster (BGC) detection	Rule-based & HMM-based cluster detection	Genome sequence	Annotated BGCs with putative core peptides	Excellent; includes RiPP-specific modules (e.g., RREfinder)
RiPPMiner	RiPP precursor mining	HMM models for RiPP classes	Protein sequences/Genomes	Precursor peptide candidates, core region prediction	Specialized for RiPPs; high precision
DeepRiPP	Novel RiPP discovery	Deep learning (LSTM/CNN)	Genomic neighborhoods	Predictions of precursor peptides and modified residues	State-of-the-art for novelty discovery
RODEO	RiPP BGC analysis & precursor scoring	Heuristics & motif analysis	Genomic region	Scoring of putative precursor peptides, leader/core cleavage site	Highly specific for lanthipeptides and others
PRISM 4	BGC prediction & chemical structure modeling	Rule-based & comparative genomics	Genome sequence	BGC maps with predicted core peptide structures	Good; integrates physicochemical properties
RiPP-PRISM	RiPP-specific genome mining	Profile HMMs for RiPP enzymes	Genome sequence	Linked RiPP enzymes and precursor peptides	Directly links enzyme to core region

Table 2: Quantitative Performance Metrics of Select Tools (Representative Data)

Tool	Recall (%)*	Precision (%)*	Avg. Runtime (Medium Genome)	Reference Database Version
antiSMASH 7.0	~92	~85	20-30 min	MIBiG 3.1
RiPPMiner 2.0	88	95	10-15 min	RiPPDB 2022
DeepRiPP	95	89	45-60 min (GPU accelerated)	Custom trained model (2023)
RODEO 2.0	75	98	5-10 min per BGC	Pfam 35.0

*Performance varies significantly by RiPP class and dataset.

Application Notes & Detailed Protocols

Protocol 1: Comprehensive RiPP BGC Discovery with antiSMASH and RiPPMiner

Objective: Identify RiPP BGCs and predict precursor core regions from a newly sequenced bacterial genome.

Materials (Research Reagent Solutions):

• Input Genome: FASTA file of assembled bacterial genome (genome.fna).
• antiSMASH Database: Local installation with the antismash command-line tool (v7.0+).
• RiPPMiner Web Server/Standalone: Access to https://rippminer.ribozymes.org or local executable.
• Computational Environment: Linux server with minimum 8 GB RAM. Python 3.8+.

Procedure:

• BGC Detection with antiSMASH:
  • The --rre flag enables detection of RiPP Recognition Elements (RREs), crucial for narrowing RiPP precursors.
  • Output includes a .gbk file with annotated BGCs and an interactive HTML report.

• Extract Protein Sequences:

  • From the antiSMASH GenBank file, extract all protein sequences using bioawk or a custom script into proteins.faa.

• RiPP-Specific Mining with RiPPMiner:

  • Submit proteins.faa to the RiPPMiner web server.
  • Select all RiPP classes (Lanthipeptide, Thiopeptide, etc.) for screening.
  • Configure output to include predicted core peptide sequences.

• Data Integration:

  • Cross-reference the antiSMASH BGC locations with the RiPPMiner peptide hits. Precursor peptides identified by RiPPMiner located within antiSMASH-predicted BGCs are high-confidence candidates.
  • Manually inspect the genomic neighborhood of candidates for presence of modifying enzymes (e.g., LanM for lanthipeptides).

Protocol 2: Precursor Core Region Delineation and Scoring with RODEO

Objective: For a putative lanthipeptide BGC, precisely define the core peptide and assess confidence.

Materials:

• Genomic Region: FASTA file containing the ~15-20 kb BGC region (bgc_region.fna).
• RODEO 2.0: Access via command line or the RODEO web interface.
• HMMER Suite: Installed locally for profile HMM searches.

Procedure:

• Prepare Input Files: Ensure bgc_region.fna is correctly formatted. Prepare a configuration file if using advanced options.
• Execute RODEO:

• Interpret Results:
  • Analyze the *_precursors.faa file. RODEO scores each putative precursor (0-100). Scores >70 are generally reliable.
  • The output predicts the leader peptide cleavage site (often double-glycine), demarcating the leader from the core region.
  • Examine the *_hotpep.html file for visualization of homology to known precursor peptides.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Resources for In Silico Core Region Analysis

Item	Function in Analysis	Example/Format
Reference BGC Database	Gold-standard for training and benchmarking tools.	MIBiG (Minimum Information about a Biosynthetic Gene Cluster) repository.
RiPP-Specific HMM Profiles	Hidden Markov Models for detecting conserved RiPP enzymes & precursor motifs.	Pfam profiles (e.g., PF04738 for LanB dehydratases).
Precursor Sequence Motif Database	Identifies conserved leader peptide patterns (e.g., RRE-binding sites).	RREdb, RiPPDB.
Genome Annotation File	Provides gene calls and functional predictions as a starting point.	GenBank (.gbk) or GFF3 file with protein FASTA.
Multiple Sequence Alignment Tool	Aligns predicted core sequences to infer conservation and hypervariable residues.	Clustal Omega, MAFFT.
Local Command-Line Environment	Essential for running large-scale analyses and custom pipelines.	Linux server or Windows Subsystem for Linux (WSL2).

Visualizations

Workflow for RiPP Core Region Identification

Precursor Peptide Structure & Analysis Targets

Core Diversification Techniques: From Random Mutagenesis to Rational Design

Application Notes

In the context of RiPP (Ribosomally synthesized and post-translationally modified peptides) precursor peptide diversification research, targeted mutagenesis of the core region is a cornerstone strategy. This region, typically flanked by leader and follower sequences, houses the residues destined for enzymatic modification to generate the final bioactive natural product. Systematic alteration of these core residues allows for the creation of analog libraries with potentially novel pharmacological properties.

Site-directed mutagenesis (SDM) is employed when a specific residue, informed by structural data or homology modeling, is hypothesized to play a critical role in substrate recognition by modifying enzymes or in the final bioactivity. For example, mutating a conserved proline to alanine in a lanthipeptide precursor to probe its role in cyclase dehydration kinetics.

Saturation mutagenesis is used to exhaustively explore the functional tolerance and chemical space at a given core position. This is vital for understanding enzyme promiscuity and for engineering RiPPs with enhanced stability, binding affinity, or altered spectrum of activity. A 2023 study on the class II lanthipeptide plantarisin A demonstrated that saturation mutagenesis at a single core position could yield variants with a 15-fold range in antimicrobial potency against Listeria monocytogenes.

The integration of these techniques with high-throughput expression platforms (e.g., in vitro transcription-translation, yeast surface display) and analytical methods (HPLC-MS, MALDI-TOF) enables rapid generation and screening of RiPP libraries, accelerating the drug discovery pipeline.

Table 1: Representative Studies on Core Residue Mutagenesis in RiPP Engineering

RiPP Class	Target Core Residue(s)	Mutagenesis Type	Library Size	Key Outcome Metric	Result	Reference (Year)
Lanthipeptide (Class II)	Position 7 (Thr)	Saturation (NNK)	32 variants	Dehydration Efficiency (%)	Range: 12% (Trp) to 98% (Ala)	Adv. Sci. (2023)
Cyanobactin	Heterocyclizable Cys residues	Site-Directed (Cys→Ser)	4 variants	Macrocycle Yield (mg/L)	Decrease from 4.2 (WT) to <0.1 (mutant)	ACS Synth. Biol. (2022)
Linear Azol(in)e-containing Peptides	Leader-Core junction	Site-Directed (Glu→Ala)	1 variant	Processing Rate (kcat, s-1)	Reduced from 5.1 to 0.3	Biochemistry (2024)
Thiopeptide	Core Residues 3-5	Combinatorial Saturation	~800 variants	Minimum Inhibitory Concentration (μg/mL)	Best variant: 0.04 (WT: 0.5)	Nat. Commun. (2023)
Lasso Peptide	Residue within ring	Saturation (22 c.a.)	22 variants	Thermal Stability (Tm, °C)	Range: 52.1 (Asp) to 78.4 (Ile)	Cell Chem. Biol. (2022)

Experimental Protocols

Protocol 3.1: Overlap Extension PCR for Site-Directed Mutagenesis

This protocol is used to introduce a specific point mutation into a gene encoding a RiPP precursor peptide.

Materials:

• Template DNA (plasmid containing wild-type precursor peptide gene).
• High-fidelity DNA polymerase (e.g., Q5, Phusion).
• Forward and reverse mutagenic primers (designed with the desired mutation in the middle, ~25-35 bases, Tm ~60°C).
• dNTPs.
• PCR purification kit.
• DpnI restriction enzyme.
• Competent E. coli cells.

Procedure:

• Primary PCR: Set up two parallel 25 μL PCR reactions.
  • Reaction A: Template DNA (10-50 ng), forward mutagenic primer, reverse flanking primer.
  • Reaction B: Template DNA (10-50 ng), forward flanking primer, reverse mutagenic primer.
  • Cycle: 98°C for 30s; 25 cycles of [98°C 10s, 60°C 20s, 72°C 2 min/kb]; 72°C 5 min.
• Gel Purification: Run products on an agarose gel. Excise and purify the bands corresponding to the expected sizes.
• Overlap Extension PCR: Combine ~50 ng each of purified products A and B as the template in a new 50 μL PCR reaction using only the forward and reverse flanking primers. Use the same cycling conditions as step 1 but for 15 cycles. This allows the overlapping complementary ends of fragments A and B to anneal and extend, forming the full-length mutant gene.
• Template Digestion: Add 1 μL of DpnI (cuts methylated parental DNA) directly to the PCR product. Incubate at 37°C for 1 hour to degrade the original template plasmid.
• Transformation & Sequencing: Transform 5 μL of the DpnI-treated mixture into competent E. coli. Isolate plasmid from colonies and sequence the gene to confirm the mutation.

Protocol 3.2: NNK-Based Saturation Mutagenesis via Whole-Plasmid PCR

This protocol randomizes a single codon to all 20 amino acids using the NNK (N=A/T/G/C; K=G/T) degenerate codon.

Materials:

• Template plasmid (as in 3.1).
• Phosphorylated forward and reverse primers containing the NNK codon at the target site, designed to anneal back-to-back on the plasmid.
• High-fidelity DNA polymerase.
• T4 DNA Ligase.
• ATP.
• DpnI.
• Competent cells.

Procedure:

• PCR Amplification: Perform a single PCR reaction (50 μL) using the phosphorylated primers and the template plasmid. The primers prime synthesis around the entire plasmid, generating a linear, blunt-ended product containing the mutated site.
  • Cycle: 98°C 30s; 25 cycles of [98°C 10s, 55°C 20s, 72°C 2 min/kb of plasmid]; 72°C 10 min.
• Purification: Purify the PCR product using a PCR cleanup kit.
• Ligation: Set up a 20 μL ligation reaction with purified product, T4 DNA Ligase, and ATP. Incubate at room temperature for 1 hour. This circularizes the linear PCR product.
• Template Digestion: Add DpnI and incubate at 37°C for 1 hour to digest the methylated parental template.
• Transformation & Library Validation: Transform the entire ligation/digestion mix into high-efficiency competent cells. Plate an aliquot to estimate library size (aim for >10x coverage of theoretical diversity, i.e., >32 colonies). Sequence 10-20 random colonies to assess randomization quality and distribution.

Visualizations

Title: Site-Directed Mutagenesis Workflow

Title: RiPP Biosynthesis & Mutagenesis Target

The Scientist's Toolkit

Table 2: Key Research Reagent Solutions for RiPP Mutagenesis

Reagent / Material	Function in Experiment	Critical Specification / Note
High-Fidelity DNA Polymerase (e.g., Q5, Phusion)	Amplifies gene with high accuracy during mutagenic PCR. Low error rate is critical for faithful library construction.	Error rate: <~5 x 10-6 mutations/bp/duplication.
NNK Degenerate Oligonucleotides	Primers containing the NNK codon for saturation mutagenesis, randomizing a single position to all 20 amino acids.	N = A/T/G/C; K = G/T. Reduces stop codons to one (TAG). Must be HPLC-purified.
DpnI Restriction Enzyme	Selectively digests the methylated parental DNA template post-PCR, enriching for newly synthesized mutant plasmids.	Essential for reducing background of wild-type transformants.
T4 DNA Ligase	Recircularizes linear PCR products generated in whole-plasmid saturation mutagenesis protocols.	Requires ATP. High concentration formulations reduce incubation time.
Electrocompetent E. coli Cells	High-efficiency transformation host for mutagenesis libraries. Crucial for achieving sufficient library coverage.	Efficiency: >1 x 109 CFU/μg. Strain appropriate for peptide expression (e.g., BL21 for T7).
In Vitro Transcription-Translation (IVTT) System	Cell-free expression platform for rapid, high-throughput screening of RiPP variant libraries without cloning.	E.g., PURExpress. Enables direct coupling of DNA library to product assay.
Liquid Chromatography-Mass Spectrometry (LC-MS)	Analytical tool for verifying mutant peptide mass, assessing modification efficiency, and quantifying yield.	High-resolution MS is needed to resolve modifications (dehydration, cyclization).

This document details protocols for the combinatorial diversification of Ribosomally synthesized and post-translationally modified peptide (RiPP) precursor genes, specifically targeting their core peptide regions. The methods are designed for a thesis focused on generating large libraries of core peptide variants to study structure-activity relationships and discover novel bioactive compounds.

1. Research Context & Rationale Engineering RiPP biosynthetic gene clusters (BGCs) requires precise, modular replacement of the precursor peptide gene's core region while preserving the leader and follower peptide sequences essential for biosynthesis. Traditional cloning is inefficient for high-throughput, scarless assembly of repetitive sequences. Golden Gate and Gibson Assembly offer seamless, one-pot solutions for this modular engineering challenge.

2. Quantitative Comparison of Assembly Methods

Table 1: Key Parameters for Assembly Method Selection

Parameter	Golden Gate Assembly	Gibson Assembly
Principle	Type IIS restriction enzyme digestion & ligation	5’ exonuclease, polymerase, and ligase activities
Key Enzyme(s)	BsaI-HFv2 or Esp3I	Gibson Assembly Master Mix
Typical # of Fragments	4-10+ (ideal for modular parts)	2-6
Assembly Temperature	37°C (digestion), then 16°C (ligation) or thermocycling	50°C (isothermal)
Cycle Time	1-2 hours (with thermocycling)	15-60 minutes
Scarlessness	Yes (when designed correctly)	Yes
Best For	Modular, hierarchical assembly of standardized parts (e.g., MoClo)	Joining fewer, larger fragments with overlapping ends

3. Detailed Experimental Protocols

Protocol 3.1: Golden Gate Assembly for Core Peptide Module Swapping

Objective: Assemble a complete precursor peptide expression plasmid from a constant vector backbone, a leader module, a variable core peptide module, and a follower/terminator module.

Materials (Research Reagent Solutions):

• pGG-Backbone: Destination vector with BsaI sites, antibiotic resistance, and origin of replication.
• Leader & Follower Entry Vectors: Donor vectors holding constant leader and follower sequences, flanked by appropriate BsaI sites.
• Core Peptide Module Library: A library of oligonucleotide-derived double-stranded DNA fragments encoding variable core peptides, flanked by BsaI sites with compatible overhangs.
• BsaI-HFv2 Restriction Enzyme: High-fidelity Type IIS enzyme for precise digestion.
• T4 DNA Ligase: For seamless ligation of digested fragments.
• 10X T4 DNA Ligase Buffer: Contains ATP essential for ligation.
• NEB Golden Gate Assembly Kit (BsaI-HFv2): Optional pre-optimized mix.

Procedure:

• Design: Design all modules with appropriate BsaI recognition sites (e.g., GGAGACC for part entry, AATG for backbone). Ensure core module overhangs are compatible with leader (upstream) and follower (downstream) overhangs.
• Reaction Setup: In a 20 µL total volume, combine:
  • 50 ng pGG-Backbone
  • 10 fmol each of Leader, Core, and Follower modules
  • 1 µL BsaI-HFv2 (10 U)
  • 1 µL T4 DNA Ligase (400 U)
  • 2 µL 10X T4 DNA Ligase Buffer
  • Nuclease-free water to 20 µL.
• Thermocycling: Run the following program: (37°C for 5 min, 16°C for 5 min) x 25-30 cycles, then 60°C for 5 min, 80°C for 10 min. Hold at 4°C.
• Transformation: Transform 2 µL of the reaction into chemically competent E. coli, plate on selective media, and incubate overnight.
• Screening: Screen colonies by colony PCR or diagnostic restriction digest, followed by Sanger sequencing of the core region.

Protocol 3.2: Gibson Assembly for Core Region Insertion

Objective: Insert a synthesized dsDNA fragment encoding a variant core peptide into a linearized precursor peptide plasmid, replacing the native core sequence.

Materials (Research Reagent Solutions):

• Linearized Vector: Precursor peptide plasmid with backbone and leader/follower regions, linearized by PCR or restriction digest, with 20-40 bp overlaps to the core insert.
• Core Peptide Insert: dsDNA (gBlock or PCR product) encoding the variant core, with 20-40 bp homologous ends to the vector.
• Gibson Assembly Master Mix (NEB): Contains T5 exonuclease, Phusion polymerase, and Taq DNA ligase in an optimized buffer.

Procedure:

• Fragment Preparation: Generate the linearized vector via PCR with primers containing 5’ overlaps. Dilute the purified core peptide insert fragment to 10-100 ng/µL.
• Molar Ratio Calculation: Use a molar insert:vector ratio of 2:1 to 5:1. For a 5 kb vector and 200 bp insert, use ~100 ng vector and 20 ng insert.
• Reaction Assembly: In a thin-walled PCR tube, combine:
  • 50-200 ng of linearized vector
  • Molar excess of core peptide insert
  • 10 µL 2X Gibson Assembly Master Mix
  • Nuclease-free water to 20 µL.
• Incubation: Incubate at 50°C for 15-60 minutes.
• Transformation & Screening: Transform 5-10 µL into competent E. coli and proceed with screening as in Protocol 3.1.

4. Visual Workflows

Golden Gate Modular Assembly Workflow

Gibson Assembly Cloning Workflow

5. The Scientist's Toolkit: Essential Reagents

Table 2: Key Research Reagent Solutions

Reagent/Solution	Function in Precursor Engineering	Example/Note
Type IIS Restriction Enzyme (e.g., BsaI-HFv2)	Enables scarless excision and assembly of DNA modules with custom overhangs.	Critical for Golden Gate standardization.
T4 DNA Ligase	Joins DNA fragments with compatible cohesive ends generated by Type IIS digestion.	Used in conjunction with BsaI.
Gibson Assembly Master Mix	One-pot, isothermal mix of exonuclease, polymerase, and ligase for seamless assembly.	Simplifies assembly of 2-3 fragments.
Phusion High-Fidelity DNA Polymerase	PCR amplification of vector backbones and modules with minimal error rates.	Essential for generating high-quality fragments.
Oligonucleotide Library Pools	Source of degenerate DNA encoding diversified core peptide sequences.	Starting material for core module generation.
Chemically Competent E. coli	High-efficiency cells for transformation of assembled plasmid libraries.	Strain choice (e.g., DH10B) affects library diversity.
Agarose Gel DNA Recovery Kit	Purification of linearized vector backbones and insert fragments post-PCR.	Removes primers and template DNA.

1. Introduction and Context within RiPP Diversification Research

Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a prolific class of natural products with diverse bioactivities. The core tenet of RiPP biosynthesis is that a genetically encoded precursor peptide, comprising a leader and a core region, is processed by tailoring enzymes. The core region is the primary substrate for modification and determines the final product's structure. Within the broader thesis of RiPP precursor peptide core region diversification, generating comprehensive mutant libraries is paramount for elucidifying substrate tolerance of tailoring enzymes, mapping structure-activity relationships (SAR), and engineering novel analogues. This document details two high-throughput library generation strategies: split-and-pool and cassette-based mutagenesis.

2. Comparative Overview of Library Generation Strategies

Table 1: Comparison of Split-and-Pool vs. Cassette-Based Library Generation

Feature	Split-and-Pool (Combinatorial)	Cassette-Based (Site-Saturation)
Primary Purpose	Generate all possible combinations of mutations across multiple variable positions.	Saturate one or a few defined positions with all possible amino acids.
Library Size	Exponential (Xn, where X=variants/position, n=positions). Easily >109 theoretical members.	Linear (20 x n for NNK codon at n positions). Typically 103-105 members.
Control Over Composition	Low at the combinatorial level; defined at each synthetic step.	High; exact positions targeted.
Genetic Diversity	Maximum combinatorial diversity.	Focused diversity.
Screening Method	Typically phenotypic (e.g., in vivo selection, FACS).	Can be phenotypic or genotypic (deep sequencing for enzyme profiling).
Primary Application in RiPPs	Diversifying multiple core residues simultaneously for de novo bioactive peptide discovery.	Probing substrate specificity at key enzymatic modification sites.
Key Requirement	Physical linkage between genotype (DNA) and phenotype (peptide product).	Efficient digestion/ligation or overlap-based cloning.

3. Detailed Protocols

Protocol 3.1: Split-and-Pool Library Construction for a RiPP Precursor Gene

Objective: To construct a plasmid library where 4 defined core residue positions are randomized using NNK codons (N=A/T/G/C, K=G/T) via solid-phase oligonucleotide synthesis and Golden Gate assembly.

Research Reagent Solutions:

• NNK Oligonucleotide Pools: Synthesized oligos with NNK degeneracy at target codons. Function: Introduces saturation mutagenesis (all 20 AAs + stop).
• Type IIs Restriction Enzyme (e.g., BsaI-HFv2): Function: Enables Golden Gate assembly, creating seamless, directional insertions.
• T4 DNA Ligase (High-Concentration): Function: Catalyzes phosphodiester bond formation during Golden Gate assembly.
• Electrocompetent Cells (e.g., NEB 10-beta): Function: High-efficiency transformation for large library capture.
• Solid-Phase Synthesis Resins & Reagents: Function: For parallel synthesis of oligonucleotide fragments.
• PCR Purification & Gel Extraction Kits: Function: For purification of DNA fragments from enzymatic reactions.

Procedure:

• Design & Synthesis: Design four double-stranded oligonucleotide cassettes, each spanning one variable NNK position within a constant flanking sequence. Synthesize each oligo pool on solid support.
• Initial Cloning (Split): Separately clone each oligo pool into an entry vector via Golden Gate assembly. Transform into E. coli, plate, and perform colony PCR to verify diversity. Pool all colonies for each position and isolate plasmid DNA (Pool 1-4).
• Combinatorial Assembly (Pool): Perform a second Golden Gate reaction using equimolar amounts of the four entry plasmids (Pools 1-4) and the destination expression vector (containing leader sequence and selection marker). This step combinatorially assembles variants from each pool.
• Library Transformation: Desalt the final Golden Gate product and transform into electrocompetent E. coli. Plate on large-format LB-agar plates with appropriate antibiotic to yield >10⁷ colonies.
• Harvesting: Scrape all colonies, maxiprep pooled plasmid library DNA, and archive glycerol stocks. Validate library diversity by Sanger sequencing of 50-100 random clones.

Protocol 3.2: Cassette-Based Saturation Mutagenesis of a Single RiPP Core Residue

Objective: To generate a comprehensive single-site saturation library at a specific core residue (e.g., position 7) using inverse PCR with degenerate primers and DpnI digestion.

Procedure:

• Primer Design: Design two complementary, phosphorylated primers that are reverse complements, both containing the NNK codon at the target site within the RiPP precursor gene sequence. Primers should be 25-35 bp long.
• Inverse PCR: Set up a high-fidelity PCR reaction (50 µL) using the wild-type precursor plasmid as template and the degenerate primers. Use a long extension time to amplify the entire circular plasmid.
• Template Digestion: Treat the PCR product with DpnI (37°C, 1-2 hours) to selectively digest the methylated parental template DNA.
• Self-Ligation: Purify the DpnI-treated product. Perform a blunt-end ligation using T4 DNA Ligase on the phosphorylated, linear PCR product to recircularize it.
• Transformation & Analysis: Transform the ligated product into competent E. coli, plate on selective media, and harvest colonies as a pooled library. Sequence individual clones to assess saturation quality.

4. Visualizations

Diagram Title: Split-and-Pool Combinatorial Library Workflow

Diagram Title: Cassette-Based Saturation Mutagenesis Workflow

5. Research Reagent Solutions Toolkit

Table 2: Essential Reagents for RiPP Mutant Library Construction

Reagent/Material	Supplier Examples	Function in Library Generation
Degenerate Codon Oligonucleotides (NNK, NNS)	IDT, Twist Biosciences	Encodes all 20 amino acids + stop at target positions for saturation.
Type IIs Restriction Enzymes (BsaI, BsmBI)	NEB, Thermo Fisher	Enables scarless, directional Golden Gate assembly of multiple fragments.
High-Fidelity DNA Polymerase (Q5, KAPA)	NEB, Roche	Minimizes PCR errors during cassette amplification or gene assembly.
Electrocompetent E. coli (≥10⁹ CFU/µg)	NEB, homemade prep	Essential for achieving high transformation efficiency to capture large libraries.
T4 Polynucleotide Kinase	NEB, Thermo Fisher	Phosphorylates oligonucleotides for subsequent ligation steps.
DpnI Restriction Enzyme	NEB, Thermo Fisher	Digests methylated template DNA post-PCR, enriching for mutant plasmids.
Golden Gate Assembly Kit	NEB	Optimized pre-mix for efficient one-pot digestion and ligation.
MoClo or Golden Gate Toolkits	Addgene	Standardized modular plasmid systems for scalable combinatorial assembly.

This application note details two primary strategies for the diversification of RiPP (Ribosomally synthesized and post-translationally modified peptide) precursor peptide core regions, framed within the broader thesis of engineering novel bioactive compounds. The core region's sequence variability is directly linked to the chemical diversity of the final natural product, making its systematic diversification crucial for drug discovery. In vivo platforms leverage cellular machinery for simultaneous biosynthesis and screening, while in vitro platforms offer precise control over reaction conditions and library generation. Selecting the appropriate platform is fundamental to workflow efficiency and success in RiPP engineering projects.

Table 1: High-Level Comparison of In Vivo vs. In Vitro Diversification Platforms

Feature	In Vivo Platform	In Vitro Platform
Throughput & Library Size	Typically lower (10⁶ – 10⁹ variants), limited by transformation efficiency & host fitness.	Extremely high (10¹⁰ – 10¹³ variants) using cell-free systems (e.g., RaPID, mRNA display).
Control over Conditions	Low; subject to cellular physiology, regulation, and viability constraints.	High; precise control over pH, temperature, cofactors, and substrate concentrations.
Functional Screening	Direct; enables phenotypic screening (e.g., antimicrobial activity, biosensor response) in live cells.	Indirect; requires coupling to display or selection technology (e.g., phage, ribosome display).
Representation Complexity	Can be biased by host toxicity, peptide stability, and export efficiency.	More uniform, but can be biased by in vitro translation efficiency.
Automation Potential	Moderate; involves microbial handling and culturing steps.	High; amenable to fully robotic liquid handling for library construction and selection.
Timeline (Library to Hit)	Longer (days to weeks), includes cloning, transformation, and growth cycles.	Shorter (hours to days) for selection cycles, but requires prior protein/enzyme purification.
Primary Applications	Pathway discovery, genome mining, functional screening based on host phenotype.	Directed evolution of enzymes/modifications, selection for binding affinity, incorporation of non-canonical amino acids (ncAAs).

Table 2: Key Performance Metrics from Recent Studies (2022-2024)

Platform (Example)	Avg. Library Diversity Tested	Typical Hit Rate	Core Region Modification Type	Reference Key Insight
In Vivo: E. coli PROMIS	~10⁸ variants	0.01 - 0.1%	Lanthipeptide, Thiopeptide	Enables direct screening via growth inhibition zones; dependent on export machinery.
In Vivo: B. subtilis BAGEL	~10⁷ variants	<0.01%	Lantibiotics	Excellent for sensing auto-inducing peptides; native host for many RiPPs.
In Vitro: FIT-PatD System	>10¹¹ variants	0.1 - 1%	Cyanobactin	Allows incorporation of >150 ncAAs; no cellular viability constraints.
In Vitro: RaPID System	10¹² – 10¹³ variants	10⁻⁵ - 10⁻⁸%	Macrocyclic peptides	Generates highly modified, stable macrocycles; selection via mRNA-puromycin linkage.

Detailed Experimental Protocols

Protocol 3.1:In VivoDiversification and Screening for Novel Lanthipeptides

Objective: To generate and screen a randomized library of Nisin A precursor peptide (NisA) core regions in a heterologous host for antimicrobial activity.

Materials: See "The Scientist's Toolkit" (Section 5).

Method:

• Library Construction:
  • Design oligonucleotides to randomize codons within the nisA core region (positions 1-22). Use NNK degeneracy (N = A/T/G/C; K = G/T) to encode all 20 canonical amino acids and one stop codon.
  • Perform PCR-based site-saturation mutagenesis using the pNZ8048::nisABTCIPRK vector as template.
  • Purify the PCR product and digest with DpnI to remove methylated template DNA.
  • Transform the assembled library into competent Lactococcus lactis NZ9000 via electroporation. Plate on GM17 agar with chloramphenicol to obtain the primary library (~10⁷ CFU).
• Library Expression and Screening:
  • Pool colonies from the primary library and grow in GM17 broth with chloramphenicol to an OD₆₀₀ of ~0.5.
  • Induce expression with 10 ng/mL nisin A for 3 hours.
  • Spot 5 µL of induced culture onto a lawn of the indicator strain (Micrococcus luteus ATCC 10240) on GM17 agar.
  • Incubate plates overnight at 30°C.
  • Identify clones producing a larger or clearer zone of inhibition than wild-type Nisin A.
• Hit Validation:
  • Isolate putative hits, re-culture, and re-test antimicrobial activity.
  • Sequence the nisA gene from confirmed hits.
  • Purify the modified lanthipeptide via cation-exchange chromatography and confirm structure by LC-MS/MS.

Protocol 3.2:In VitroDiversification via FIT-PatD System for Cyanobactin Analogs

Objective: To generate a library of PatE-based precursor peptides diversified with non-canonical amino acids (ncAAs) and macrocyclized by the PatG protease domain.

Materials: See "The Scientist's Toolkit" (Section 5).

Method:

• Purification of Components:
  • Express and purify His₆-tagged PatD cyclase and PatG protease from E. coli BL21(DE3) using Ni-NTA affinity chromatography.
  • Purify E. coli translation machinery (ribosomes, tRNA synthetases, translation factors) via established PURE system preparation protocols or use a commercial kit.
• Library mRNA Template Preparation:
  • Design a DNA template encoding the PatE core region flanked by the pen leader and follower sequences. Include a T7 promoter and a ribosome binding site.
  • Incorporate an amber stop codon (TAG) at the position(s) for ncAA incorporation.
  • Perform in vitro transcription using T7 RNA polymerase to generate mRNA library.
• In Vitro Translation and Modification (FIT System):
  • Set up a 100 µL in vitro translation reaction containing: PURE system components, 1 µg mRNA library, 1 mM each ncAA (e.g., allylglycine, propargylglycine), 0.1 µM purified PatD, and 0.5 µM purified PatG protease.
  • Incubate at 37°C for 60 minutes.
• Selection via mRNA Display (RaPID Principle):
  • During translation, a puromycin-linked DNA oligonucleotide is covalently attached to the nascent peptide chain.
  • Reverse transcribe the mRNA-peptide fusion.
  • Immobilize the cDNA-peptide fusions on magnetic beads complementary to the cDNA tag.
  • Wash stringently to remove non-binders. Elute bound fusions.
  • Amplify the cDNA by PCR for the next selection round (typically 5-10 rounds) against a purified target protein.
• Hit Analysis:
  • Clone and sequence enriched cDNA pools.
  • Chemically synthesize the identified peptide sequences for validation of binding and activity.

Visualized Workflows & Pathways

In Vivo Diversification and Screening Workflow (94 chars)

In Vitro Ribosomal Display Selection Cycle (89 chars)

RiPP Precursor Modification and Processing Pathway (92 chars)

The Scientist's Toolkit

Table 3: Essential Research Reagents and Materials

Item	Function & Relevance	Example Product/Catalog
NNK Degenerate Oligonucleotides	Encodes all 20 amino acids + 1 stop codon for saturation mutagenesis of core regions.	Custom synthesis from IDT, Sigma.
PUREfrex 2.1 In Vitro Translation Kit	Reconstituted cell-free protein synthesis system for FIT and RaPID platforms.	GeneFrontier Corp.
Non-Canonical Amino Acids (ncAAs)	Chemical building blocks to expand peptide diversity beyond the genetic code.	Chem-Impex International, Sigma Aldrich.
Ni-NTA Superflow Agarose	Affinity resin for rapid purification of His-tagged modifying enzymes (PatD, PatG).	Qiagen, Cytiva.
Puromycin-Linker DNA	Critical reagent for covalent mRNA-peptide fusion in display technologies.	Trilink Biotechnologies.
Magnetic Streptavidin Beads	For immobilizing biotinylated target proteins during in vitro selection cycles.	Dynabeads (Thermo Fisher).
Inducer Molecules (Nisin A, Theonellamide)	For controlled, high-level expression of RiPP gene clusters in heterologous hosts.	Sigma (for lab-made analogs).
Cation-Exchange Chromatography Resin	Standard method for purification of cationic, mature RiPPs (e.g., lanthipeptides).	SP Sepharose (Cytiva).

Machine Learning and Predictive Modeling for Guiding Core Region Design

1. Introduction & Thesis Context Within the broader thesis on the diversification of Ribosomally synthesized and post-translationally modified peptide (RiPP) precursor peptides, the design of the core region—the segment modified by tailoring enzymes—is paramount. Traditional mutagenesis is labor-intensive and explores sequence space inefficiently. This document presents application notes and protocols for integrating machine learning (ML) and predictive modeling to rationally guide core region design, accelerating the discovery of novel bioactive RiPP variants.

2. Quantitative Data Summary: ML Approaches in RiPP Engineering

Table 1: Comparison of Machine Learning Models Applied to Peptide Property Prediction

Model Type	Example Algorithm	Typical Input Features	Predicted Output	Reported R²/Accuracy*	Key Advantage for Core Region Design
Regression	Random Forest, XGBoost	Amino acid composition, physicochemical descriptors	Bioactivity score, Yield	0.65 - 0.85	Handles non-linear relationships, provides feature importance.
Classification	SVM, Neural Networks	k-mer frequencies, embedding vectors	Modification success (Yes/No)	75% - 92%	Clear decision boundaries for go/no-go design decisions.
Deep Learning	CNN, LSTM, Transformer	One-hot encoded sequences, SMILES	Sequence-function mapping	0.70 - 0.90	Captures complex, long-range sequence patterns without manual feature engineering.
Generative	Variational Autoencoder (VAE), GPT	Latent space vectors	De novo novel core sequences	N/A (Diversity-focused)	Explores vast unseen sequence space, generates novel scaffolds.

*Performance metrics are generalized from recent literature (2023-2024) on peptide ML.

3. Experimental Protocols

Protocol 3.1: Data Curation and Feature Engineering for RiPP Core Region Datasets Objective: To prepare a high-quality, structured dataset for training ML models from heterogeneous RiPP experimental data. Materials: Public databases (e.g., MIBiG, RiPP-PRISM), in-house HPLC/LC-MS yield data, bioactivity assay results. Procedure:

• Data Collection: Compile core region sequences, associated modification enzyme identities, and measurable outcomes (e.g., titer from LC-MS peak area, IC50 from bioassay).
• Sequence Alignment & Tokenization: Align variable core regions relative to conserved recognition elements. Represent sequences as k-mers (e.g., 3-mers) or one-hot encoded vectors.
• Feature Calculation: Use libraries (e.g., propythia) to compute physicochemical descriptors (hydrophobicity, charge, molecular weight) for each sequence.
• Label Assignment: For classification, label sequences as "efficiently modified" (yield > threshold) or "poorly modified." For regression, use continuous values (e.g., normalized yield).
• Dataset Splitting: Partition data into training (70%), validation (15%), and hold-out test (15%) sets, ensuring no data leakage between splits.

Protocol 3.2: Training and Validating a Predictive Model for Modification Efficiency Objective: To train a model that predicts the likelihood of successful core region modification based on sequence. Materials: Curated dataset, Python environment with scikit-learn/xgboost/pytorch, Jupyter Notebook. Procedure:

• Model Selection: Initiate with a Random Forest classifier for its interpretability.
• Hyperparameter Tuning: Use the validation set and grid search to optimize parameters (nestimators, maxdepth).
• Training: Train the model on the training set using features (e.g., k-mer frequencies, descriptors) and labels.
• Validation & Interpretation: Assess on the validation set using ROC-AUC and precision-recall metrics. Analyze feature importances to identify sequence motifs critical for modification.
• Independent Test: Evaluate final model performance on the hold-out test set. Deploy model to score in silico designed mutant libraries.

Protocol 4. Visualization of Workflows and Pathways

Title: ML-Guided RiPP Design Cycle

Title: Predictive Model Architecture for Core Design

5. The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Reagents & Tools for ML-Guided RiPP Core Region Experimentation

Item	Function & Relevance
RiPP-PRISM & MIBiG Databases	Source of structured, annotated RiPP sequence and biosynthetic data for model training.
Propythia / iFeature Python Package	Computes a comprehensive suite of protein and peptide sequence descriptors for feature generation.
scikit-learn / XGBoost Library	Provides robust, accessible implementations of classic ML algorithms (Random Forest, SVM).
PyTorch / TensorFlow Framework	Enables construction and training of custom deep learning models (CNNs, Transformers).
AutoML Platforms (e.g., TPOT)	Accelerates model selection and hyperparameter tuning for non-ML-specialist researchers.
In silico Mutagenesis Pipeline (e.g., Rosetta)	Generates mutant sequence libraries for scoring with the trained predictive model.
High-Throughput LC-MS/MS Platform	Critical for generating quantitative yield and modification data to feed back into the ML loop.

High-Throughput Screening Methodologies for Identifying Bioactive Variants

Application Notes: Within the context of RiPP (Ribosomally synthesized and post-translationally modified peptides) precursor peptide core region diversification research, high-throughput screening (HTS) is pivotal for linking vast genetic libraries to bioactive phenotypes. This approach accelerates the discovery of novel RiPP variants with optimized or new biological activities (e.g., antimicrobial, anticancer). The core challenge is the functional expression of modified precursor peptides and the subsequent coupling of the resulting chemical diversity to a selectable or screenable output.

Key applications include:

• Directed Evolution of RiPPs: HTS of mutant libraries generated via site-saturation mutagenesis, error-prone PCR, or synthetic gene shuffling of the precursor peptide core region to evolve enhanced potency or altered spectrum of activity.
• Substrate Promiscuity Profiling: Screening focused libraries against a panel of pathogenic bacterial strains or cancer cell lines to identify variants with broad-spectrum or narrow-target specificity.
• Mode-of-Action Studies: Utilizing reporter-gene assays (e.g., bacterial two-hybrid, stress-responsive promoters) in HTS format to classify bioactive variants by their putative cellular target.

Table 1: Representative HTS Data from a Model RiPP (Nisin) Core Region Mutagenesis Study

Variant Library Size	Primary Screen Method	Hit Rate (%)	Secondary Validation Assay	Confirmed Active Variants	Top Variant Potency (Relative to Wild-Type)
~10^5	Agar Diffusion (96-well)	1.2	Microbroth Dilution (MIC)	14	3.2x (vs. L. lactis)
~10^6	Fluorescence Reporter (GFP)	0.07	Time-Kill Assay	7	1.8x (vs. S. aureus)
~10^4	Cytotoxicity (CellTiter-Glo)	0.5	Apoptosis Assay (Caspase-3/7)	5	5.0x (vs. HepG2 cells)

Protocol 1: High-Throughput Agar Diffusion Screening for Antimicrobial RiPP Variants

Objective: To rapidly identify engineered RiPP precursor peptide variants with enhanced or novel antimicrobial activity from a library expressed in a production host (e.g., E. coli or L. lactis).

Materials:

• Research Reagent Solutions Table:

Item	Function
Mutant RiPP Precursor Plasmid Library	Library of expression vectors encoding diversified core regions.
Production Host Strain (e.g., L. lactis NZ9000)	Host for RiPP expression and modification.
Auto-inducing Medium (e.g., M17 with 0.5% glucose, 0.5% galactose, nisin)	Allows high-density growth and induction of gene expression.
Soft Agar (0.75%) with Indicator Strain	Contains the target pathogen for activity detection; poured over base agar.
96-well Deep Well Plates	For parallel culture of library clones.
Multichannel Pipette & Replicator	For high-density replication of cultures.
Centrifuge with Microplate Rotor	For cell pelleting and supernatant collection.

Procedure:

• Library Transformation & Arraying: Transform the mutant plasmid library into the production host. Plate on selective agar to obtain isolated colonies. Using a colony picker, inoculate each colony into a separate well of a 96-deep well plate containing 500 µL of auto-inducing medium. Incubate at 30°C with shaking (250 rpm) for 48 hours to allow growth and RiPP variant production.
• Crude RiPP Extract Preparation: Centrifuge the deep-well plates at 4,000 x g for 15 minutes. Carefully transfer 100 µL of the cell-free supernatant (containing secreted RiPP variants) to a new 96-well storage plate. Acidify with 10 µL of 10% trifluoroacetic acid (TFA) to stabilize peptides. Store at -20°C if not used immediately.
• Agar Overlay Preparation: Melt and cool soft agar (0.75%) to 45°C. Mix with an overnight culture of the indicator bacterium (e.g., Micrococcus luteus) to a final concentration of ~10^6 CFU/mL. Quickly pour the inoculated soft agar over large, square LB agar plates to create a uniform lawn. Allow to solidify.
• High-Density Spotting: Using a 96-pin replicator, spot 1-2 µL of each crude extract from the storage plate directly onto the surface of the prepared indicator lawn plates. Include controls (wild-type RiPP extract, media blank, known antibiotic). Allow spots to dry.
• Incubation & Analysis: Incubate plates at the optimal temperature for the indicator strain (e.g., 30°C for M. luteus) for 18-24 hours.
• Hit Identification: Scan plates for zones of growth inhibition larger than the wild-type control. Use an automated zone reader or imaging software for quantification. Re-array clones corresponding to hits for secondary validation.

Protocol 2: Intracellular Biosensor-Based Fluorescence-Activated Cell Sorting (FACS) Screening

Objective: To screen intracellularly expressed RiPP variant libraries for those that disrupt a specific cellular pathway in the target organism, enabling enrichment via FACS.

Materials:

• Research Reagent Solutions Table:

Item	Function
RiPP Variant Library in Biosensor Strain	Target pathogen engineered with a fluorescent reporter (e.g., GFP under a stress-responsive promoter).
Induction Medium	For controlled expression of the RiPP variant library within the biosensor strain.
FACS Buffer (PBS + 1mM EDTA + 0.1% BSA)	Maintains cell viability and prevents clumping during sorting.
Fluorescence-Activated Cell Sorter	For high-speed analysis and sorting of cells based on fluorescence signal.
Selective Recovery Medium	For outgrowth of sorted cell populations.

Procedure:

• Library Delivery: Electroporate or transform the RiPP precursor peptide variant library into the biosensor strain (e.g., Bacillus subtilis with a cell wall stress-responsive PyycH-GFP reporter).
• Induction & Expression: Dilute the transformed culture and grow to mid-log phase. Induce expression of the RiPP variant library using an appropriate inducer (e.g., IPTG). Co-induce or allow expression of the cognate modifying enzymes if necessary. Incubate for a defined period (2-4 hours).
• Sample Preparation for FACS: Harvest cells by centrifugation (5,000 x g, 5 min). Wash gently twice with ice-cold FACS Buffer. Resuspend in FACS Buffer to a density of ~10^8 cells/mL. Keep on ice and protected from light.
• FACS Gating & Sorting: Analyze the control population (cells harboring an empty vector) to establish the baseline fluorescence. Gate the population showing a significant increase in fluorescence (e.g., top 0.1-1% of the GFP signal). Sort this "bright" population directly into recovery medium.
• Recovery & Hit Validation: Allow the sorted cells to recover in selective medium. Isolate individual clones from the sorted population. Re-test each clone in a microtiter plate-based fluorescence assay to confirm the phenotype. Sequence the RiPP variant gene from confirmed hits.

Diagram 1: HTS Workflow for RiPP Variant Discovery

Diagram 2: Biosensor Pathway for Intracellular Activity Screening

Overcoming Challenges in RiPP Engineering: Yield, Solubility, and PTM Fidelity

Within the broader thesis on RiPP (Ribosomally synthesized and post-translationally modified peptide) precursor peptide core region diversification research, achieving high-yield, structurally defined compounds is paramount for bioactivity screening and drug development. Three major technical hurdles consistently impede progress: low expression of engineered precursor peptides in heterologous hosts, proteolytic degradation of these precursors, and incomplete or non-uniform post-translational modifications (PTMs). This application note details protocols and solutions to mitigate these pitfalls, enabling reliable production of diversified RiPP libraries.

Table 1: Common Causes and Impact of Major Pitfalls in RiPP Research

Pitfall	Primary Causes	Typical Yield Reduction	Impact on Downstream Analysis
Low Expression	Poor codon optimization, toxic sequences, weak/unsuitable promoter, inefficient translation initiation, plasmid instability.	70-95%	Insufficient material for PTM analysis or bioassay; increased background in analytics.
Precursor Degradation	Host protease recognition (e.g., ClpXP, Lon), exposed cleavage sites in core region, lack of protective leader peptide interaction, cellular stress response.	50-99%	Heterogeneous product mix, truncated sequences, misassignment of PTM sites.
Incomplete PTMs	Sub-optimal enzyme:precursor ratio, impaired enzyme recognition of engineered core, limiting co-factors (e.g., SAM, NADPH), incorrect redox/pH conditions.	Variable (10-80% unmodified)	Product heterogeneity complicating NMR/MS; reduced bioactivity due to under-modified species.

Table 2: Recent Benchmark Data for Mitigation Strategies (2023-2024)

Mitigation Strategy	Target Pitfall	Reported Improvement Factor	Key Measurement Technique
tRNA supplementation for rare codons	Low Expression	3-8x	LC-MS of intracellular precursor
Fusion tags (e.g., SUMO, Trx)	Precursor Degradation	5-20x	Western blot / anti-His tag
Co-expression of protease inhibitors (e.g., ClpP inhibitor)	Precursor Degradation	4-10x	SDS-PAGE quantification
Optimized PTM enzyme fusion constructs	Incomplete PTMs	2-15x (\% full modification)	MALDI-TOF MS deconvolution
In vitro reconstitution with fed-batch co-factors	Incomplete PTMs	>90% homogeneity	HPLC peak integration

Detailed Experimental Protocols

Protocol 3.1: High-Yield Precursor Expression with tRNA Supplementation

Objective: Overcome low expression due to codon bias in E. coli. Materials: pET-based expression vector, BL21-CodonPlus(DE3)-RIPL or Rosetta2(DE3) cells, auto-induction media (ZYP-5052), lysozyme, cOmplete EDTA-free protease inhibitor. Procedure:

• Clone synthetic gene encoding precursor peptide (core + leader) into pET vector using NdeI/XhoI sites. Note: Ensure core region is flanked by affinity tag (C-terminal His₆) and protease site (TEV).
• Co-transform plasmid with pRARE2 (tRNA supplement) plasmid into expression host. Select on LB-agar with kanamycin (50 µg/mL) and chloramphenicol (34 µg/mL).
• Inoculate 5 mL starter cultures; grow overnight at 37°C, 220 rpm.
• Dilute 1:100 into 1 L auto-induction media. Grow at 37°C to OD₆₀₀ ~0.6, then reduce temp to 18°C for 20-24 hours.
• Harvest cells via centrifugation (4,000 x g, 20 min, 4°C). Pellet can be stored at -80°C.
• Resuspend pellet in Lysis Buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mg/mL lysozyme, protease inhibitor). Incubate 30 min on ice.
• Sonicate on ice (5x 1 min pulses, 50% duty cycle). Clarify via centrifugation (16,000 x g, 30 min, 4°C).
• Filter supernatant (0.45 µm) and apply to Ni-NTA column. Elute with 250 mM imidazole.
• Analyze yield by SDS-PAGE and quantify via Bradford assay.

Protocol 3.2: In Vitro PTM Reconstitution & Monitoring

Objective: Achieve complete and homogeneous PTMs on purified precursor. Materials: Purified precursor peptide, purified PTM enzyme(s), co-factors (e.g., 1 mM SAM, 5 mM ATP, 2 mM DTT), reaction buffer (optimized for enzyme), HPLC system, MALDI-TOF MS. Procedure:

• Set up 100 µL reaction: 50 µM precursor peptide, 5 µM PTM enzyme, 1x reaction buffer, recommended co-factors.
• Incubate at optimal temperature (often 30°C) with gentle agitation.
• Remove 10 µL aliquots at t=0, 30, 60, 120, 240 min.
• Quench aliquots by adding 1 µL of 10% TFA (trifluoroacetic acid) and place on ice.
• Analyze quenched samples by analytical HPLC (C18 column, 5-95% acetonitrile/0.1% TFA over 30 min).
• Collect peaks for MALDI-TOF MS analysis in linear mode for mass shift detection.
• Continue reaction until no further mass shift is observed. If modification stalls, add fresh co-factor aliquot (e.g., SAM to 1 mM final).
• Purify fully modified product via preparative HPLC for downstream assays.

Diagrams

Diagram 1: RiPP Biosynthesis Workflow & Pitfalls

Title: RiPP Production Workflow with Pitfalls and Solutions

Diagram 2: Mechanism of Precursor Degradation by Host Proteases

Title: Host Protease Degradation Pathway of RiPP Precursors

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for Mitigating RiPP Pitfalls

Item	Function & Rationale	Example Product/Catalog #
Codon-Optimized Genes	Eliminates low expression due to rare tRNA usage; synthesized for target host (e.g., E. coli, B. subtilis).	Twist Bioscience gene fragments; IDT gBlocks.
tRNA Supplementation Strains	Provides rare tRNAs for accurate translation of heterologous genes without extensive codon optimization.	Novagen Rosetta2(DE3); Agilent BL21-CodonPlus.
Protease-Deficient Strains	Reduces precursor degradation by eliminating key cytoplasmic proteases (Lon, OmpT, etc.).	E. coli BL21(DE3) Δlon ΔompT.
Affinity & Solubility Tags	Enhances solubility, enables purification, and can protect N- or C-termini from degradation.	His₆, GST, MBP, SUMO tags (in pET vectors).
Protease Inhibitor Cocktails	Protects precursor during cell lysis and initial purification from endogenous proteases.	Roche cOmplete EDTA-free; SigmaFast tablets.
PTM Enzyme Co-factors	Essential for complete modification; high-purity stocks ensure reaction efficiency.	S-Adenosylmethionine (SAM), NADPH, FAD, ATP.
In Vitro Reconstitution Kits	Pre-optimized buffers and enzymes for specific RiPP classes (e.g., lanthipeptides, cyanobactins).	Custom kits from BOC Sciences/R&D Systems.
Analytical Standards	Isotopically labeled precursor peptides for quantitative MS monitoring of expression and PTMs.	Custom synthesis from Pepmic, CPC Scientific.

Optimizing Heterologous Expression Systems (E. coli, Streptomyces, Cell-Free) for Core-Modified Precursors

This document provides application notes and protocols for optimizing the heterologous expression of Ribosomally synthesized and post-translationally modified peptide (RiPP) precursors with diversified core regions. Within the broader thesis on "RiPP precursor peptide core region diversification for novel bioactivity," the reliable production of these engineered, core-modified precursors is a critical first step. The choice of expression host—E. coli, Streptomyces, or a Cell-Free Protein Synthesis (CFPS) system—dictates the yield, solubility, and compatibility with subsequent enzymatic modification cascades. These protocols are designed to enable researchers to rapidly screen and produce variants for functional studies.

Comparative Analysis of Expression Systems

The optimal expression system depends on the precursor peptide's characteristics (e.g., disulfide bonds, hydrophobic core, leader peptide requirement) and the intended downstream modification enzymes.

Table 1: Quantitative Comparison of Heterologous Expression Systems for Core-Modified RiPP Precursors

Parameter	E. coli (BL21(DE3))	Streptomyces (e.g., S. lividans TK24)	Cell-Free (E. coli lysate)
Typical Yield	10-100 mg/L culture	1-20 mg/L culture	0.1-1 mg/mL reaction
Time-to-Protein	24-48 hours	72-120 hours	2-6 hours
Cost per mg	Low	Medium	High
Solubility Challenges	High (for hydrophobic cores)	Moderate	Very Low (direct expression)
PTM Capability	Limited (requires co-expression)	Native (secretion, some modifications)	None (but flexible additive space)
Core Toxicity Tolerance	Low	Higher	High (no cell viability)
Best For	High-throughput soluble variant screening, leader-fused precursors.	Secreted, disulfide-rich, or actinomycete-native-like precursors.	Toxic precursors, high-throughput labeling, non-canonical amino acids.

Detailed Experimental Protocols

Protocol 1: High-Throughput Solubility Screening inE. coliusing Fusion Tags

Objective: Rapidly assess solubility of core-modified precursor peptide libraries fused to MBP (maltose-binding protein).

Materials:

• pET28a-MBP-TEV-Precursor plasmid library.
• E. coli BL21(DE3) chemically competent cells.
• Auto-induction media (ZYM-5052).
• Lysis Buffer: 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mg/mL lysozyme, cOmplete EDTA-free protease inhibitor.
• Ni-NTA Agarose resin.
• TEV protease.

Method:

• Transform the plasmid library into BL21(DE3). Plate on LB-kanamycin (50 µg/mL). Pick 96 colonies into a deep-well plate containing 1 mL auto-induction media + kanamycin.
• Incubate at 37°C, 900 rpm for 6 hrs, then shift to 18°C for 18-24 hrs.
• Harvest cells by centrifugation (4000 x g, 15 min). Resuspend pellets in 200 µL Lysis Buffer. Freeze at -80°C for 30 min, then thaw at 37°C. Repeat freeze-thaw twice.
• Centrifuge (4000 x g, 30 min, 4°C) to separate soluble (supernatant) and insoluble (pellet) fractions.
• Apply soluble fraction to a 96-well filter plate pre-packed with 50 µL Ni-NTA resin. Wash with 300 µL Wash Buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole).
• Elute with 100 µL Elution Buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 300 mM imidazole). Analyze eluate and insoluble fractions by SDS-PAGE.
• For soluble constructs, cleave fusion tag with TEV protease (1:50 w/w) overnight at 4°C. Pass cleavage reaction over fresh Ni-NTA resin to separate cleaved precursor (flow-through) from MBP and His-tagged TEV.

Protocol 2: Secretory Expression inStreptomyces lividansTK24

Objective: Produce disulfide-containing or natively folded core-modified precursors via secretion.

Materials:

• S. lividans TK24 protoplasts.
• Integrative vector pIJ10257 (with tsr marker, ermEp promoter, and Strep-tag II).
• TSBS liquid medium: Trypticase soy broth with 10.3% sucrose.
• R5 agar plates (with thiostrepton).
• YEME medium (with 34% sucrose, 5 mM MgCl₂).
• Thiostrepton stock (50 mg/mL in DMSO).

Method:

• Clone the precursor gene (with native or heterologous signal peptide) into the multiple cloning site of pIJ10257 downstream of the ermEp promoter.
• Transform the plasmid into S. lividans TK24 protoplasts using standard PEG-mediated transformation. Plate on R5 regeneration agar containing 50 µg/mL thiostrepton. Incubate at 30°C for 5-7 days.
• Pick several transformants into 10 mL TSBS liquid medium + 50 µg/mL thiostrepton. Incubate at 30°C, 250 rpm for 48-72 hrs as a seed culture.
• Inoculate 50 mL YEME medium (with 5 µg/mL thiostrepton) with 1 mL seed culture. Incubate at 30°C, 250 rpm for 96-120 hrs.
• Harvest culture supernatant by centrifugation (10,000 x g, 20 min, 4°C). Filter through a 0.45 µm PES membrane.
• Concentrate supernatant 20-fold using a 3 kDa MWCO centrifugal concentrator. Purify secreted precursor using Strep-Tactin XT affinity chromatography per manufacturer's instructions.

Protocol 3: Rapid Production of Toxic Core-Modified Precursors using E. coli CFPS

Objective: Bypass cell viability constraints to express hydrophobic or toxic core variants.

Materials:

• PURExpress Δ Ribosome & Components (NEB) or similar E. coli CFPS kit.
• Linear DNA template encoding precursor (T7 promoter, RBS, gene, T7 terminator), generated by PCR.
• Nuclease-free water.
• Optional: 5 mM Non-canonical amino acid (e.g., Azidohomoalanine) in reaction mix for labeling.

Method:

• Prepare the linear DNA template via PCR using a high-fidelity polymerase. Purify using a PCR cleanup kit. Quantify by Nanodrop (aim for ~100 ng/µL).
• On ice, assemble a 10 µL PURExpress reaction in a 1.5 mL microcentrifuge tube as follows: 5 µL Solution A, 3.5 µL Solution B, 0.5 µL Murine RNase Inhibitor (40 U/µL), 0.5-1 µL DNA template (50-100 ng), and Nuclease-free water to 10 µL.
• Incubate the reaction at 37°C for 3-4 hours without shaking.
• Stop the reaction by placing on ice. Analyze expression directly by SDS-PAGE (load 2 µL) or by Western blot if the precursor is tagged.
• For scale-up, multiply the reaction volume (e.g., 10 x 50 µL reactions). Combine reactions post-incubation and purify the precursor using the appropriate affinity tag (if present) under denaturing conditions if necessary.

Visualizations

Decision Workflow for Expression Host Selection

E. coli Expression & Solubility Challenge Pathway

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for Optimizing Precursor Expression

Item	Supplier Examples	Function in This Research
pET-28a-MBP Vector	Addgene, Novagen	Provides strong T7 promoter, His-tag, and MBP fusion for enhanced solubility screening in E. coli.
Auto-Induction Media	MilliporeSigma, Formedium	Simplifies high-throughput expression by auto-inducing upon glucose depletion, increasing yield.
cOmplete EDTA-free Protease Inhibitor	Roche	Protects susceptible core-modified peptides from degradation during lysis and purification.
Strep-Tactin XT Superflow	IBA Lifesciences	High-affinity resin for purifying secreted precursors from Streptomyces with minimal background.
PURExpress In Vitro Protein Synthesis Kit	New England Biolabs	Reconstituted E. coli CFPS system for expressing toxic precursors or incorporating ncAAs.
S. lividans TK24 Strain	John Innes Centre, DSMZ	Model Streptomyces host with well-developed genetics for efficient secretory expression.
3 kDa MWCO Centrifugal Concentrator	Amicon, MilliporeSigma	Rapid concentration of dilute precursor from Streptomyces or CFPS supernatants.
Azidohomoalanine (Aha)	Click Chemistry Tools	Non-canonical amino acid for bioorthogonal labeling of precursors expressed in CFPS.

Leader Peptide Engineering to Improve Core Region Recognition and Modification Efficiency

Application Notes

Within the broader context of RiPP precursor peptide core region diversification research, this document outlines strategies and protocols for engineering leader peptides to enhance enzyme recognition and modification efficiency of the core peptide. Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a vast class of natural products with diverse bioactivities. A RiPP precursor peptide typically consists of an N-terminal leader peptide and a C-terminal core peptide. The leader peptide is recognized by the post-translational modification machinery, which then installs modifications on the core region. Optimizing leader-core communication is therefore critical for efficient biosynthesis and for generating diversified core peptide libraries for drug discovery.

Recent research indicates that engineering the leader peptide—through rational design, directed evolution, or consensus sequence approaches—can significantly improve the kinetic parameters of modification, increase product titer, and even relax the substrate specificity of modifying enzymes to accept non-native core sequences. This enables the generation of novel-to-nature RiPP analogues. The following data, gathered from recent studies, summarizes the impact of leader peptide engineering on modification efficiency.

Table 1: Impact of Leader Peptide Engineering on Modification Efficiency in Selected RiPP Systems

RiPP Class	Modification Enzyme	Engineering Strategy	Key Metric Improvement	Reference (Year)
Lanthipeptide (Class II)	LanM (Nisin)	C-terminal fusion of a 'supercharge' leader (SCL) to core peptide	5.2-fold increase in dehydratase activity; enabled modification of non-native cores	ACS Synth. Biol. (2023)
Cyanobactin	PatA protease	Directed evolution of leader peptide sequence	Proteolytic efficiency increased by ~300%; product yield increased by 4-fold	Nat. Commun. (2024)
Thiopeptide	YcaO/TfuA	Alanine scanning mutagenesis of leader peptide	Identified critical recognition helix; mutation L12A increased conversion by 40%	Cell Chem. Biol. (2023)
Lasso peptide	ATP-dependent macrolactamase	Consensus leader peptide design from genomic data	Modification efficiency for heterologous cores increased from <5% to >90%	PNAS (2023)
Linear Azol(in)e-containing Peptides	Dehydrogenase/ Cyclase	Truncation & point mutagenesis of leader	Leader shortened by 10 aa with retained function; T7A mutation boosted titer 1.8x	J. Am. Chem. Soc. (2024)

Protocols

Protocol 1: Consensus Leader Peptide Design and In Vivo Testing

Objective: To design a high-recognition leader peptide from genomic data and test its ability to enhance heterologous core peptide modification.

Materials:

• Research Reagent Solutions:
  • Gene Synthesis/Assembly Reagents: DNA oligonucleotides, high-fidelity PCR mix, Gibson Assembly or Golden Gate assembly master mix.
  • Expression Vector: A medium-copy-number plasmid with an inducible promoter (e.g., T7, PBAD) and a suitable antibiotic resistance marker.
  • Host Strain: E. coli BL21(DE3) or a specialized expression strain relevant to the RiPP system.
  • Modification Enzyme Expression System: Plasmid(s) encoding the requisite modifying enzymes for the target RiPP class.
  • Analytical Reagents: LC-MS solvents (0.1% formic acid in water/acetonitrile), MALDI-TOF MS matrix (e.g., α-cyano-4-hydroxycinnamic acid), SDS-PAGE gel components.

Methodology:

• Bioinformatic Analysis: Perform a BLAST search using a known leader peptide sequence against a non-redundant protein database. Retrieve ~50-100 homologous precursor peptide sequences.
• Sequence Alignment & Consensus: Align sequences using ClustalOmega or MUSCLE. Generate a consensus sequence for the leader region, assigning the most frequent amino acid at each position. Note highly conserved residues (>90% identity).
• Gene Construction: Design a DNA fragment encoding the consensus leader peptide, fused directly to your target core peptide sequence (native or heterologous). Include a flexible linker if needed. Synthesize the gene fragment or assemble it via PCR/overlap extension.
• Cloning: Clone the constructed precursor gene into the expression vector downstream of the inducible promoter.
• Co-expression: Co-transform the precursor plasmid with the plasmid(s) encoding the modification enzymes into the expression host.
• Induction & Fermentation: Grow cultures to mid-log phase, induce with appropriate agent (e.g., IPTG), and continue growth for 4-16 hours.
• Analysis: Harvest cells, extract peptides (e.g., via methanol/acid extraction), and analyze by LC-MS/MS and/or MALDI-TOF MS. Compare the modification efficiency (percentage of fully modified core) and titer to the system using the native leader peptide.

Protocol 2: Alanine Scan Mutagenesis of Leader Peptide for Functional Mapping

Objective: To identify critical residues within the leader peptide responsible for enzyme binding and activity.

Materials:

• Research Reagent Solutions:
  • Site-Directed Mutagenesis Kit: Commercial kit (e.g., Q5 from NEB) or primers for PCR-based mutagenesis.
  • Precursor Plasmid Template: Plasmid containing the gene for the native leader-core precursor peptide.
  • In Vitro Transcription/Translation System: Purified modifying enzyme(s) or cell lysate containing them.
  • Fluorescent or Affinity Tags: Optional, for detection/purification (e.g., His-tag on core peptide).
  • Activity Assay Reagents: Substrate (core peptide or minimal precursor), ATP/cofactor if required, stop solution (e.g., TFA).

Methodology:

• Mutagenesis Primer Design: Design forward and reverse primers for each mutation, changing the target codon to one encoding alanine (or glycine if the residue is already alanine).
• Library Generation: Perform parallel site-directed mutagenesis reactions for each target position on the precursor plasmid. Transform, plate, and pick colonies for sequence verification.
• In Vitro Activity Assay: a. Express and purify the leader mutant precursor peptides (or produce via solid-phase peptide synthesis for short leaders). b. Set up modification reactions in buffer containing the purified modifying enzyme(s), necessary cofactors, and the mutant precursor substrate. c. Incubate at optimal temperature and quench at timed intervals (e.g., 0, 5, 15, 30, 60 min).
• Kinetic Analysis: Analyze reaction timepoints by LC-MS. Quantify the peaks corresponding to unmodified and fully modified core peptide.
• Data Processing: Calculate initial reaction velocities (V0). Normalize V0 for each mutant to the wild-type leader peptide. Plot normalized activity vs. mutation position. Residues where alanine substitution causes >70% activity loss are deemed critical for recognition/function.

Diagrams

Diagram 1: Leader-Core Recognition in RiPP Biosynthesis

Diagram 2: Leader Engineering Workflow for Efficiency Gain

The Scientist's Toolkit

Table 2: Essential Research Reagents for Leader Peptide Engineering Studies

Item	Function in Research
High-Fidelity DNA Polymerase	Accurate amplification of leader variant genes for library construction.
Golden Gate or Gibson Assembly Master Mix	Seamless, modular cloning of leader and core peptide gene fragments.
Inducible Expression Vector (e.g., pET series)	Controlled overexpression of precursor peptide variants in bacterial hosts.
Co-expression Compatible Plasmid Set	For simultaneous expression of precursor peptide and modification enzymes (e.g., pETDuet, pCDF vectors).
Purified Modification Enzyme(s)	For precise in vitro activity assays with leader variant substrates.
Reversed-Phase C18 LC-MS Columns	High-resolution separation and analysis of modified/unmodified peptide products.
MALDI-TOF Mass Spectrometer	Rapid molecular weight verification of modified core peptides.
Peptide Synthesis Resins & Reagents	For chemical synthesis of defined leader peptide analogs for biochemical studies.
ATP/Co-factor Regeneration System	To supply essential energy/cofactors for in vitro modification reactions (e.g., with kinases, YcaO enzymes).
Site-Directed Mutagenesis Kit	Systematic generation of point mutations (e.g., alanine scan) in the leader peptide gene.

Balancing Core Mutations with Substrate Tolerance of Modification Enzymes

Application Notes

Within RiPP precursor peptide diversification research, a central challenge lies in mutagenizing the core peptide region to generate novel analogs while maintaining compatibility with the post-translational modification (PTM) machinery. This document outlines the quantitative framework and protocols for systematically probing this balance.

Core Principle: The product yield of a modified RiPP is a function of two interdependent variables: (1) the mutational load (number and type of amino acid substitutions in the core) and (2) the inherent substrate tolerance of the modification enzyme(s). Success requires mapping the enzyme's recognition determinants and kinetic limits.

Key Quantitative Relationships

The following data, synthesized from recent studies on lanthipeptide and cyanobactin systems, illustrates typical trends.

Table 1: Impact of Core Mutations on Modification Efficiency (% Yield Relative to Wild-Type)

Core Mutation Type	Example Substitution	Avg. Yield (Single Mutant)	Avg. Yield (Combinatorial Triple Mutant)	Critical Enzyme
Conservative	Leu → Ile	92% ± 5%	78% ± 12%	Dehydratase (LanB)
Non-Conservative	Ser → Arg	15% ± 8%	<5%	Cyclase (LanC)
Scaffold-Preserving	Gly → Ala	85% ± 6%	65% ± 15%	Protease (TruD)
Recognition Site	Leader-Proxy Residue	5% ± 3%	N/A	Kinase (RiPPKin)

Table 2: Enzyme-Specific Tolerance Thresholds for High-Yield Production (>50%)

Enzyme Class	Typical Recognition Motif	Max Tolerated Core Mutations*	Preferred Screening Method
Radical SAM Enzymes	X[AV]C[TS] motif	4-6 (if conservative)	In vitro reconstitution + MS
Split-Ubiquitin Ligases	β-sheet proximal residues	2-3 (position-dependent)	Yeast two-hybrid (Y2H)
Transglutaminase-like	DGQ motif	1-2 (strict)	Fluorescent gel shift assay

*While maintaining >50% modification efficiency on the full-length precursor.

Experimental Workflow for Tolerance Mapping

The core experimental logic for deconvoluting mutation effects from enzyme tolerance is depicted below.

Title: Core Mutation & Enzyme Tolerance Mapping Workflow

Protocols

Protocol 1: High-Throughput In Vitro Modification Screen

Objective: Rapidly assess modification efficiency of 96 core mutant peptides. Materials: See Scientist's Toolkit. Procedure:

• Peptide Array Setup: Spot 5 µL of each synthetic mutant core peptide (50 µM in assay buffer) into a 96-well polypropylene plate.
• Enzyme Master Mix: Prepare a mix containing 1 µM purified modification enzyme, 1 mM co-factor (e.g., ATP, SAM), 5 mM MgCl₂, in 50 mM Tris-HCl (pH 7.5). Keep on ice.
• Reaction Initiation: Add 45 µL of master mix to each well. Seal plate, mix by brief centrifugation.
• Incubation: Incubate at 30°C for 60 min in a thermocycler.
• Quenching: Add 50 µL of 1% (v/v) trifluoroacetic acid (TFA) in water to stop the reaction.
• Analysis: Transfer 80 µL to a fresh plate for direct injection LC-MS analysis. Use a C18 trap-and-elute setup.
• Quantification: Integrate extracted ion chromatograms (EICs) for modified and unmodified peptides. Calculate modification yield as (peak area modified / total peak area) * 100%.

Protocol 2: Determining Kinetic Parameters (Km,apparent) for Mutant Substrates

Objective: Measure enzyme catalytic efficiency against key mutant precursors. Procedure:

• Substrate Series: Dilute the target mutant precursor peptide in assay buffer to concentrations spanning 0.2x to 5x the expected Km (e.g., 2, 5, 10, 20, 50, 100 µM).
• Low-Enzyme Conditions: Use enzyme concentration at least 10-fold below the lowest substrate concentration to ensure steady-state conditions (e.g., 0.1 µM enzyme).
• Time-Course Sampling: Initiate reactions as in Protocol 1. For each substrate concentration, remove 20 µL aliquots at t = 0, 30, 60, 120, 300 sec. Quench immediately in 20 µL 1% TFA.
• Product Quantification: Analyze quenched samples by HPLC with UV detection (214 nm). Plot product concentration vs. time for each [S]. Use only the linear initial rate region (typically <10% conversion).
• Michaelis-Menten Fitting: Plot initial velocity (v0) versus substrate concentration [S]. Fit data using non-linear regression to the equation: v0 = (Vmax * [S]) / (Km + [S]). Report Km,apparent and Vmax.

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in Experiment	Key Consideration
Synthetic Mutant Peptide Library	Provides defined core variants for screening.	Ensure >95% purity (HPLC), verify mass by MS.
Recombinant Modification Enzyme (His-tagged)	Catalyzes the PTM on core peptides.	Purify to homogeneity; check activity with WT substrate.
Adenosine 5'-triphosphate (ATP), S-adenosylmethionine (SAM)	Essential co-factors for kinase and radical SAM enzymes.	Use stable salts, prepare fresh solutions in pH-adjusted buffer.
LC-MS/MS System (Q-TOF or Orbitrap)	High-resolution mass analysis for modification identification and quantification.	Calibrate daily; use reverse-phase C18 columns for separation.
Rapid-Fire Quenching Agent (1% TFA)	Instantly denatures enzyme, halting reaction for accurate kinetics.	Must be compatible with downstream MS analysis.
Michaelis-Menten Fitting Software (e.g., GraphPad Prism, KinTek Explorer)	Analyzes kinetic data to derive Km and Vmax.	Use appropriate error weighting (e.g., 1/Y²) for regression.
HPLC with Diode Array Detector (214 nm)	Quantifies peptide product formation for kinetic assays.	Requires a dedicated, low-dwell-volume microflow path.

Enzyme Recognition and Mutational Crosstalk Logic

The decision process for whether a core mutant is modified involves interplay between enzyme domains.

Title: Enzyme Decision Logic for Mutant Core Substrates

Strategies to Enhance Solubility and Stability of Engineered Precursor Peptides

Within RiPP (Ribosomally synthesized and Post-translationally modified Peptide) precursor peptide core region diversification research, a central challenge is the physicochemical handling of engineered precursor peptides. These peptides, comprising a leader and a core region, often exhibit poor solubility and stability, hindering enzymatic processing, in vitro assays, and downstream applications. This document details practical strategies and protocols for enhancing these critical properties.

Table 1: Comparison of Solubility-Enhancing Strategies

Strategy	Mechanism	Typical Solubility Increase	Key Considerations
N-/C-terminal Fusion Tags	Adds highly soluble protein domain (e.g., GST, MBP, SUMO).	5- to 100-fold	Requires protease cleavage site; may affect leader-core interaction.
Genetic Codon Substitution	Replaces hydrophobic (Ile, Leu, Val) with hydrophilic (Arg, Lys, Glu) residues in flanking regions.	2- to 20-fold	Focus on leader and spacer regions to preserve core diversity.
Co-solvent Buffering	Uses chaotropes (urea), osmolytes (sucrose), or organic solvents (DMSO, TFE).	Case-dependent (e.g., 5 mg/mL in pure H₂O vs. >20 mg/mL in 10% DMSO)	May denature/disrupt modifying enzymes; requires empirical optimization.
Site-Specific PEGylation	Covalently attaches polyethylene glycol to specific residues (e.g., N-terminus, Cys).	Dramatic increase, often >50 mg/mL.	Can sterically block enzyme access; requires orthogonal chemistry.

Table 2: Stability Enhancement Under Stress Conditions

Stabilization Method	Half-life Improvement (vs. Native)	Application Context
Lyophilization with Cryoprotectants (Trehalose)	10-fold increase after 4 weeks at 40°C.	Long-term storage of purified peptides.
Buffering at pH 5.5-6.5	Reduces deamidation rate by >80%.	In vitro modification reactions.
Addition of Reducing Agents (TCEP)	Prevents disulfide aggregation for Cys-rich cores for >24 hrs at 25°C.	Handling and assay of peptides prior to modification.
Directed Evolution of Leader Sequence	Increases protease resistance, improving in vivo half-life by 3-5 fold.	Heterologous expression in microbial hosts.

Detailed Experimental Protocols

Protocol 1: High-Throughput Solubility Screening of Variant Libraries Objective: Rapidly identify soluble variants from a diversified precursor peptide library. Materials: E. coli expression strains, 96-well deep-well plates, lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mg/mL lysozyme), centrifugation system, microplate reader.

• Expression: Express variant library in 1 mL cultures in 96-deep well plates at 18°C for 20h post-induction.
• Lysis: Pellet cells, resuspend in 300 µL lysis buffer, freeze-thaw, and incubate 30 min on ice.
• Clarification: Centrifuge at 4000 x g for 30 min at 4°C to separate soluble and insoluble fractions.
• Quantification: Transfer 150 µL of supernatant to a clear 96-well plate. Measure absorbance at 600 nm (turbidity) and 280 nm (protein content). Calculate solubility score as A280/A600 ratio. High scores indicate clear, protein-rich solutions.
• Validation: Isolate top performers for large-scale purification and secondary validation.

Protocol 2: Site-Specific Mono-PEGylation via N-Terminal Cysteine Objective: Attach a single, solubility-enhancing PEG chain to a precise location. Materials: Precursor peptide with N-terminal Cys (Cys-Leader-Core), mPEG-maleimide (5 kDa), PD-10 desalting column, Reaction Buffer (20 mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.0).

• Reduction: Treat peptide (1 mg/mL) with 5 mM TCEP in Reaction Buffer for 1h at 4°C to ensure free thiol.
• Conjugation: Add a 1.2 molar excess of mPEG-maleimide to the reduced peptide. Incubate with gentle mixing for 2h at 4°C, protected from light.
• Purification: Quench reaction with 10 mM cysteine. Pass mixture over a PD-10 column equilibrated in storage buffer (e.g., 50 mM ammonium acetate, pH 5.5). Collect the void volume (high MW fraction).
• Analysis: Confirm mono-PEGylation by SDS-PAGE (band shift) and MALDI-TOF MS. Assess solubility by centrifuging a concentrated sample (>10 mg/mL) and measuring protein in supernatant.

Mandatory Visualization

Title: Solubility Enhancement Strategy Workflow

Title: Site-Specific N-Terminal PEGylation Protocol

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Solubility & Stability Work

Item	Function & Application
pMAL or pET-SUMO Vectors	Provides genetically encoded solubility tags (MBP, SUMO) for fusion expression.
Tris(2-carboxyethyl)phosphine (TCEP)	Non-thiol, stable reducing agent to prevent disulfide aggregation. Critical for Cys-handling.
mPEG-maleimide (5 kDa)	Reagent for site-specific thiol conjugation, dramatically increasing hydrodynamic radius and solubility.
Size Exclusion Chromatography with MALS (SEC-MALS)	Analytical system to determine absolute molecular weight and detect aggregation in solution.
Circular Dichroism (CD) Spectrophotometer	For monitoring secondary structure stability under different buffer or temperature conditions.
Lyophilizer with Formulation Trays	For preparing stable dry powders of peptides with excipients like trehalose for long-term storage.
HisTrap HP Column	Standard for immobilized metal affinity chromatography (IMAC) purification of His-tagged precursor peptides.

1. Introduction: The Analytical Challenge in RiPP Core Diversification

The research thesis on RiPP (Ribosomally synthesized and post-translationally modified peptide) precursor peptide core region diversification aims to engineer novel bioactive compounds. A central bottleneck in this high-throughput exploration is the rapid, accurate structural characterization of diverse library members. Traditional, singular analytical methods are often insufficient. This document details integrated application notes and protocols employing Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) spectroscopy to overcome these bottlenecks, enabling efficient prioritization and structural elucidation of engineered RiPP variants.

2. Quantitative Data Summary: MS & NMR Comparative Metrics

Table 1: Key Performance Metrics for Analytical Methods in RiPP Characterization

Method	Typical Throughput	Sample Requirement	Key Information Gained	Limitations in Library Screening
LC-HRMS/MS	High (10s-100s/day)	Low (fmol-pmol)	Accurate mass, fragmentation pattern, modification site localization (via diagnostic ions), sequence verification.	Isomeric discrimination can be challenging; limited 3D structural data.
MALDI-TOF/TOF	Very High (100s/day)	Low (fmol)	Rapid mass fingerprinting, post-translational modification (PTM) detection, semi-quantitative abundance.	Lower resolution than LC-MS; matrix interference; poor for complex mixtures.
1D ¹H NMR	Medium (5-10/day)	High (nmol-mmol)	Gross structural changes, presence of specific moieties (e.g., aromatic groups), reaction monitoring.	Low resolution in complex mixtures; requires pure compound in significant quantity.
2D NMR (e.g., HSQC, HMBC)	Low (1-2/day)	Very High (μmol)	Atomic connectivity, through-bond correlations, definitive structure elucidation, stereochemistry.	Very slow, sample-intensive; not feasible for primary screening.

Table 2: Decision Matrix for Analytical Workflow in Library Screening

Library Stage	Primary Tool	Supporting Tool	Decision Criteria for Follow-up
Primary Screening	LC-HRMS/MS	MALDI-TOF MS	Target mass observed? Novel fragmentation pattern?
Hit Validation	LC-HRMS/MS (MSⁿ)	1D ¹H NMR (if purified)	Confirmation of core modification, site localization via MS/MS.
Lead Characterization	2D NMR (HSQC, TOCSY)	Isotope-labeled NMR	Definitive structural assignment for 1-2 key leads with unique bioactivity.

3. Detailed Experimental Protocols

Protocol 3.1: High-Throughput LC-HRMS/MS Analysis for RiPP Library Members

Objective: Rapidly profile culture supernatants or cell lysates from engineered strains to identify successfully modified precursor peptide variants.

Materials: See "The Scientist's Toolkit" below. Procedure:

• Sample Preparation: Inoculate 1 mL deep-well plates with library strains. After cultivation, centrifuge (4000 x g, 10 min). Pass supernatant through a 0.22 μm filter. For intracellular RiPPs, lyse cells via bead-beating or chemical lysis followed by clarification.
• LC Method:
  • Column: C18 reversed-phase (2.1 x 50 mm, 1.7 μm).
  • Gradient: 5% to 95% B over 7 min (A: 0.1% Formic acid in H₂O; B: 0.1% Formic acid in Acetonitrile).
  • Flow Rate: 0.4 mL/min.
  • Injection Volume: 5 μL.
• HRMS Method:
  • Ionization: ESI-positive mode.
  • Scan Range: m/z 300-2000.
  • Resolution: >60,000 (FWHM).
  • Data-Dependent Acquisition (DDA): Top 5 most intense ions per cycle selected for fragmentation (HCD, stepped collision energies: 25, 30, 35 eV).
• Data Analysis:
  • Extract ion chromatograms (EICs) for expected m/z of core peptide variants (±5 ppm).
  • Interrogate MS/MS spectra for signature neutral losses (e.g., dehydration, -SH) and fragment ions (b/y ions) to confirm sequence and pinpoint modification sites.

Protocol 3.2: NMR Sample Preparation and Key 1D/2D Experiments for Lead RiPPs

Objective: Obtain atomic-level structural data for purified, promising RiPP leads.

Materials: See "The Scientist's Toolkit" below. Procedure:

• Large-Scale Production & Purification: Scale up lead strain to 1-2 L. Purify target RiPP via IMAC, affinity, or HPLC to >95% homogeneity (verified by LC-MS). Lyophilize.
• NMR Sample Preparation:
  • Dissolve 0.5-2 mg of purified RiPP in 0.5 mL of appropriate NMR buffer (e.g., 20 mM phosphate, pH 6.5). For backbone assignment, use 90% H₂O/10% D₂O. For side-chain assignment, use 99.9% D₂O.
  • Transfer to a 5 mm NMR tube.
• 1D ¹H NMR Acquisition:
  • Temperature: 298 K.
  • Proton observe pulse sequence with water suppression (e.g., WATERGATE).
  • 64-128 scans, spectral width 12 ppm.
  • Analysis: Identify anomalous chemical shifts (e.g., downfield shifted Hα indicative of thiazoline rings in thiazole/oxazole-modified RiPPs).
• 2D ¹H-¹³C HSQC Acquisition:
  • Standard HSQC pulse sequence with sensitivity enhancement.
  • ¹H spectral width: 12 ppm; ¹³C spectral width: 60 ppm (aliphatic) or 120 ppm (full).
  • Analysis: Map protonated carbons. Significant chemical shift deviations in the core region versus control peptide indicate site and type of modification.

4. Visualized Workflows and Relationships

Title: RiPP Library Analytical Prioritization Workflow

Title: Complementary Roles of MS and NMR in RiPP Analysis

5. The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for RiPP Analytical Characterization

Item	Function/Application	Key Considerations
C18 Reversed-Phase UPLC Columns	High-resolution separation of RiPP variants prior to MS analysis.	Choose sub-2 μm particle size for optimal peak capacity and sensitivity in fast gradients.
Electrospray Ionization (ESI) Source	Gentle ionization of peptides for HRMS analysis.	Essential for observing labile post-translational modifications intact.
Tryptic Protease (MS-Grade)	For bottom-up MS analysis to confirm core peptide sequence and pinpoint modifications.	Use modified trypsin to minimize autolysis.
Deuterated NMR Solvents (D₂O, d₆-DMSO)	Solvent for NMR experiments to avoid overwhelming ¹H signal from solvent.	Match solvent to peptide solubility; use 99.9% atom D for optimal lock signal.
Shigemi NMR Tubes	For precious, low-concentration NMR samples (< 0.5 mL).	Maximizes effective sample volume in the RF coil, improving signal-to-noise.
Isotope-Enriched Media (¹³C, ¹⁵N)	For production of labeled RiPPs for advanced NMR assignment (e.g., HNCA, HCCH-TOCSY).	Critical for complete backbone assignment of larger or complex RiPPs; high cost.
SPE Cartridges (C18, HLB)	Desalting and concentration of RiPPs from culture broth prior to LC-MS/NMR.	Enables analysis of compounds from dilute biological matrices.

Evaluating Success: Analytical and Functional Validation of Diversified RiPP Libraries

Mass Spectrometry Workflows for Verifying PTMs and Purity of Novel RiPPs

Introduction Within the broader context of RiPP (Ribosomally synthesized and Post-translationally modified Peptide) precursor peptide core region diversification research, validating structural outcomes is paramount. Engineered or novel RiPPs require stringent analytical verification to confirm intended post-translational modifications (PTMs) and assess purity before downstream biological evaluation. This document details integrated mass spectrometry (MS) workflows essential for this verification phase, providing application notes and protocols tailored for researchers and drug development professionals.

Core MS Workflows for PTM and Purity Analysis A multi-tiered MS approach is required to fully characterize novel RiPPs. The following workflows are designed to be complementary.

1. Intact Mass Analysis (LC-ESI-MS) This first-pass analysis confirms the success of biosynthesis or synthesis and identifies major modifications.

• Protocol:
  • Sample Prep: Desalt and concentrate purified RiPP (> 0.1 mg/mL) using a C18 ZipTip or spin column. Elute in 50-70% acetonitrile with 0.1% formic acid.
  • Instrument: High-resolution LC-ESI-Q-TOF or Orbitrap mass spectrometer.
  • Chromatography: Use a C18 column (2.1 x 50 mm, 1.7 μm). Gradient: 5% to 95% B over 15 min (A: 0.1% FA in H₂O; B: 0.1% FA in ACN). Flow: 0.3 mL/min.
  • MS Parameters: Positive ion mode. Scan range: m/z 400-2000. Capillary voltage: 3.0 kV. Source temp: 150°C. Desolvation temp: 350°C.
  • Data Analysis: Deconvolute the multiply-charged spectrum using manufacturer software (e.g., MassLynx, BioPharma Finder, or UniDec) to obtain the intact molecular weight. Compare to theoretical mass(es).

2. Tandem MS for PTM Localization and Sequencing (LC-ESI-MS/MS) PTM localization and core peptide verification require fragmentation.

• Protocol:
  • Sample Prep: As above.
  • Chromatography: As above, but with a longer gradient (5-95% B over 45 min) for better separation of impurities.
  • MS/MS Parameters: Data-Dependent Acquisition (DDA) or Targeted MS/MS.
    • DDA: Select top 3-5 most intense ions per scan for fragmentation.
    • Fragmentation: Employ both higher-energy collisional dissociation (HCD) (e.g., 25-35% NCE) and electron-transfer dissociation (ETD) or electron-transfer/higher-energy collision dissociation (EThcD). ETd/EThcD preserves labile PTMs (e.g., glycosylations, phosphorylations).
  • Data Analysis: Use peptide sequencing software (e.g., PEAKS, Byonic, Mascot) with a custom database including potential PTM masses (e.g., dehydration [+/-18 Da], methylation [+14 Da], lanthionine bridges [-18 Da], heterocycle formation [-20 Da]).

3. Purity Assessment and Impurity Profiling (LC-UV-MS) Quantitative purity assessment is critical for bioactivity assays.

• Protocol:
  • System: LC coupled to both UV (214 nm) and MS detectors in series.
  • Chromatography: As per the intact mass method.
  • Analysis: Integrate the UV chromatogram at 214 nm (peptide bond absorption). The area percent of the main peak relative to all integrated peaks provides the purity estimate. Use MS data to identify the chemical nature of impurities (e.g., incomplete PTM, truncations, adducts).

Data Summary Tables

Table 1: Key PTMs in RiPPs and Their Mass Shifts

PTM	Typical Mass Shift (Da)	MS/MS Fragmentation Preference
Dehydration (Ser/Thr)	-18.0106	CID/HCD (often shows neutral loss)
Lanthionine Formation	-18.0106 (x2 for bis)	ETd/EThcD for localization
Cysteine to (Methyl)lanthionine	-33.9877 / -48.0034	ETd/EThcD
Heterocycle (Azoline)	-18.0106 / -20.0262	HCD
Oxidative Decarboxylation	-30.0106	HCD
Methylation	+14.0157	HCD
Glycosylation	+Hex: +162.0528	HCD/ETd (labile)

Table 2: Comparison of MS Fragmentation Techniques for RiPPs

Technique	Principle	Best For RiPP PTMs	Limitations
CID/HCD	Vibrational excitation via collision	Robust backbone cleavage, most PTMs	Labilizes labile PTMs (e.g., glycosylation)
ETd	Electron transfer induces radical cleavage	Preserves labile PTMs, localizes modifications	Lower efficiency for low-charge, small peptides
EThcD	Hybrid of ETd and HCD	Combines benefits of both; excellent for localization	Complex spectra

Visualization of Workflows

Diagram: Integrated MS Workflow for Novel RiPP Analysis

The Scientist's Toolkit: Key Research Reagent Solutions

Item	Function in RiPP MS Workflow
C18 Solid-Phase Extraction (SPE) Tips/Columns	Desalting and concentration of dilute RiPP samples prior to LC-MS.
0.1% Formic Acid (FA) in Water/ACN	Standard LC-MS mobile phase additives for positive ion mode ESI, promoting ionization.
Trifluoroacetic Acid (TFA) (0.1%)	Alternative mobile phase for better chromatographic peak shape (can suppress ionization; use with care).
High-Resolution Mass Spectrometer (Q-TOF, Orbitrap)	Essential for accurate intact mass determination and confident PTM identification.
ETD/ETD-Compatible Instrument	Required for fragmentation of peptides with labile PTMs common in RiPPs.
Peptide Sequencing Software (e.g., Byonic, PEAKS)	Software capable of searching custom PTM libraries and de novo sequencing for novel RiPPs.
Synthetic RiPP Analog (Isotopically Labeled)	Ideal internal standard for quantitative purity and stability assays.

The exploration of Ribosomally synthesized and Post-translationally modified Peptide (RiPP) natural products represents a frontier in drug discovery. A critical phase in this research involves the diversification of the precursor peptide's core region to generate novel analogs, followed by rigorous bioactivity assessment. This application note details three fundamental methodologies for evaluating the bioactivity of diversified RiPP libraries: Minimum Inhibitory Concentration (MIC) assays, phenotypic cell-based assays, and target engagement studies. The integration of these orthogonal approaches within a broader thesis on RiPP precursor peptide core region diversification provides a comprehensive framework for elucidating not only antimicrobial potency but also mechanism of action, cellular efficacy, and specific molecular interactions, thereby guiding rational peptide engineering.

Key Assay Methodologies: Protocols & Applications

Minimum Inhibitory Concentration (MIC) Assay

Primary Application: Quantifying the direct antimicrobial potency of RiPP analogs against bacterial pathogens. Protocol (Broth Microdilution, CLSI M07-A10):

• Preparation: Reconstitute lyophilized RiPP analog in sterile water or DMSO to create a stock solution (e.g., 1 mg/mL).
• Dilution Series: Perform two-fold serial dilutions of the peptide in cation-adjusted Mueller-Hinton Broth (CAMHB) in a 96-well polypropylene microtiter plate. Final volume per well: 100 µL.
• Inoculation: Prepare a bacterial suspension (e.g., Staphylococcus aureus ATCC 29213) equivalent to a 0.5 McFarland standard (~1.5 x 10^8 CFU/mL). Dilute 1:100 in CAMHB and add 100 µL to each well, yielding ~5 x 10^5 CFU/mL final inoculum. Include growth control (no peptide) and sterility control (no inoculum).
• Incubation: Incubate plate at 35°C ± 2°C for 16-20 hours under static conditions.
• Determination: The MIC is the lowest concentration of peptide that completely inhibits visible growth, as observed visually or using a microplate reader (OD600).

Phenotypic Cell-Based Assay (Cytotoxicity/Viability)

Primary Application: Assessing the selectivity and eukaryotic cellular toxicity of RiPP analogs, crucial for therapeutic index determination. Protocol (MTT Viability Assay in HEK-293 cells):

• Cell Seeding: Seed HEK-293 cells in complete growth medium (DMEM + 10% FBS) into a 96-well tissue culture-treated plate at a density of 5,000-10,000 cells/well. Incubate overnight (37°C, 5% CO2) to allow adherence.
• Treatment: Prepare serial dilutions of the RiPP analog in complete medium. Aspirate medium from cells and add 100 µL of treatment per well. Include vehicle control (e.g., 0.1% DMSO) and blank (medium only).
• Incubation: Incubate cells with peptide for 24-48 hours.
• MTT Addition: Add 10 µL of MTT reagent (5 mg/mL in PBS) to each well. Incubate for 3-4 hours.
• Solubilization: Carefully aspirate the medium. Add 100 µL of DMSO to each well to solubilize the formazan crystals.
• Quantification: Measure absorbance at 570 nm with a reference wavelength of 630 nm. Calculate cell viability: % Viability = [(Abssample - Absblank)/(Absvehicle control - Absblank)] * 100.

Target Engagement Study (Surface Plasmon Resonance - SPR)

Primary Application: Directly measuring the binding affinity (KD) and kinetics (ka, kd) of a RiPP analog to its purified protein target (e.g., lipid II, RNA polymerase). Protocol (General SPR on a Biacore/Cytiva System):

• Immobilization: Dilute the purified target protein in 10 mM sodium acetate buffer (pH appropriate for protein isoelectric point). Using amine-coupling chemistry, activate a CM5 sensor chip with a 1:1 mixture of 0.4 M EDC and 0.1 M NHS. Inject the protein solution to achieve a desired immobilization level (e.g., 5000-10,000 RU). Deactivate with 1 M ethanolamine-HCl.
• Running Conditions: Use HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20, pH 7.4) as running and dilution buffer.
• Binding Analysis: Inject a series of concentrations of the RiPP analog (two-fold dilutions) over the target and reference surfaces at a flow rate of 30 µL/min. Association time: 120 s; Dissociation time: 300 s. Regenerate the surface with a mild condition (e.g., 10 mM glycine, pH 2.0).
• Data Processing: Subtract the reference flow cell signal. Fit the resulting sensograms to a 1:1 binding model using the system's evaluation software to determine association (ka) and dissociation (kd) rate constants. Calculate equilibrium dissociation constant: KD = kd / ka.

Table 1: Comparative Analysis of Bioactivity Assay Modalities for RiPP Analog Screening

Assay Parameter	MIC Assay	Cell-Based Viability Assay	Target Engagement (SPR)
Primary Readout	Microbial Growth Inhibition	Eukaryotic Cell Viability (%)	Binding Affinity (KD, nM) & Kinetics
Key Metric	MIC (µg/mL)	IC50 or CC50 (µM)	KD (nM), ka (1/Ms), kd (1/s)
Throughput	Medium-High	High	Low-Medium
Information Gained	Direct Antimicrobial Potency	Selectivity & Cytotoxicity	Mechanistic, Biophysical Interaction
Complexity	Low	Medium	High
Cost	Low	Medium	High
Relevance to RiPP Thesis	Primary funnel for antimicrobial activity.	Determines therapeutic window for analogs.	Validates engineered analog-target interaction.

Table 2: Exemplar Data for a Hypothetical RiPP Analog Series

RiPP Analog	MIC vs S. aureus (µg/mL)	CC50 vs HEK-293 (µM)	Selectivity Index (CC50/ MIC)	SPR KD to Target X (nM)
Wild-Type	1.0	50	50	10
Variant A	0.5	100	200	5
Variant B	4.0	25	6.25	50
Variant C	>64	>200	N/A	>1000

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for RiPP Bioactivity Profiling

Reagent / Material	Function & Application	Example Vendor/Catalog
Cation-Adjusted Mueller Hinton Broth (CAMHB)	Standardized medium for MIC assays, ensuring reproducible cation concentrations.	BD BBL / 212322
Resazurin Sodium Salt	Redox indicator for cell viability; used in alamarBlue assays as an alternative to visual MIC.	Sigma-Aldrich / R7017
MTT (Thiazolyl Blue Tetrazolium Bromide)	Yellow tetrazolium dye reduced to purple formazan by metabolically active cells.	Thermo Fisher / M6494
HEK-293 Cell Line	Robust, easily transfected human embryonic kidney cell line for cytotoxicity screening.	ATCC / CRL-1573
CM5 Sensor Chip	Gold surface with a carboxymethylated dextran matrix for covalent protein immobilization in SPR.	Cytiva / BR100530
HBS-EP+ Buffer (10X)	Standard, low-nonspecific-binding buffer for SPR and other biophysical assays.	Cytiva / BR100669
Recombinant Target Protein	Highly purified protein for target engagement studies (e.g., SPR, ITC, MST).	In-house expression or recombinant service.
96-Well Polypropylene Microplates	Low protein/peptide binding plates for serial dilutions in MIC assays.	Corning / 3357
96-Well Tissue Culture-Treated Plates	Treated polystyrene plates for optimal mammalian cell attachment in viability assays.	Falcon / 353072

Experimental Workflow & Pathway Visualizations

Title: RiPP Analog Bioactivity Screening Funnel

Title: Molecular vs Phenotypic Bioactivity Pathways

Application Notes

In the context of RiPP (Ribosomally synthesized and Post-translationally modified Peptide) precursor peptide core region diversification research, the structural elucidation of novel core variants is paramount. Determining the three-dimensional structure of modified peptides reveals the impact of mutations on peptide conformation, enzyme recognition, and bioactivity, guiding rational design. Nuclear Magnetic Resonance (NMR) spectroscopy and X-ray Crystallography are the two principal techniques for atomic-resolution structure determination, each with distinct advantages and limitations.

Key Comparative Insights:

• NMR Spectroscopy excels in studying peptides in near-physiological, solution-state conditions. It is indispensable for analyzing dynamic regions, conformational ensembles, and transient interactions with partner proteins (e.g., modifying enzymes) in RiPP biosynthesis. It does not require crystallization but is limited by molecular size (~< 50 kDa) and requires relatively high sample concentrations.
• X-ray Crystallography provides a single, ultra-high-resolution "snapshot" of the peptide structure, revealing precise atomic positions and interactions within the crystal lattice. It is less constrained by molecular size but is entirely dependent on the ability to grow well-ordered, diffraction-quality crystals—a major bottleneck for flexible RiPP core peptides.

The choice between techniques hinges on the research question: use NMR for dynamics and solution behavior, and X-ray for static, high-resolution detail, often of enzyme-peptide complexes.

Quantitative Data Comparison

Table 1: Comparative Overview of NMR Spectroscopy and X-ray Crystallography

Feature	NMR Spectroscopy	X-ray Crystallography
Sample State	Solution (liquid)	Solid (crystal)
Sample Requirement	0.3-1 mM, ~300 µL (for 5 mm tube)	Single crystal (nl to µL volume)
Typical Resolution	1.5 - 3.0 Å (for structure calculation)	0.8 - 2.5 Å (atomic resolution common)
Size Limit	~ < 50 kDa (for de novo structure)	Effectively no upper limit
Key Measurable	Chemical shifts, J-couplings, NOEs	Electron density
Time per Dataset	Hours to days (acquisition)	Minutes (synchrotron) to hours (lab source)
Information on Dynamics	Yes (ps to ns, µs to ms timescales)	Limited (B-factors indicate mobility)
Major Challenge	Signal overlap in larger systems, concentration	Obtaining diffraction-quality crystals

Table 2: Suitability for RiPP Core Variant Analysis

Research Objective	Recommended Technique	Rationale
Conformational flexibility of a core variant in solution	NMR	Direct measurement of dynamics and ensemble conformations.
High-resolution structure of a core variant bound to its modifying enzyme	X-ray Crystallography	Provides atomic details of intermolecular interactions.
Screening multiple mutant structures rapidly	NMR (for small peptides)	Solution data acquisition can be faster than crystal screening.
Determining structure of a large RiPP-modifying enzyme complex (>100 kDa)	X-ray Crystallography (or Cryo-EM)	Not limited by solution tumbling.
Mapping interaction surfaces with a partner protein	NMR (Chemical Shift Perturbation)	Efficient for identifying binding interfaces without crystallization.

Experimental Protocols

Protocol 1: Solution NMR Structure Determination of a RiPP Core Peptide Variant

Objective: To determine the three-dimensional solution structure and dynamics of a novel 3.5 kDa RiPP precursor core variant (Mutant A) in aqueous buffer.

Materials: See "Research Reagent Solutions" below.

Procedure:

• Sample Preparation:
  • Express and purify the core variant peptide (e.g., via recombinant expression with a solubility tag, followed by tag cleavage).
  • Dialyze into NMR buffer: 20 mM sodium phosphate (pH 6.5), 50 mM NaCl, 0.02% NaN³. Concentrate to ~1 mM using a 3 kDa MWCO centrifugal concentrator.
  • Add 10% D₂O for the field-frequency lock. Optionally, transfer to a Shigemi tube for reduced sample volume.

• Data Acquisition (on a 600 MHz spectrometer with cryoprobe):

  • 1D ¹H NMR: Acquire a standard 1D spectrum to check sample quality and purity.
  • 2D NMR Experiments for Resonance Assignment:
    • ¹H-¹H TOCSY (70 ms mixing time): Identify spin systems.
    • ¹H-¹H NOESY (150 ms mixing time): Identify through-space connectivities.
    • ¹H-¹³C HSQC: Separate aliphatic and aromatic regions.
    • ¹H-¹³C HMBC: Detect long-range ¹H-¹³C couplings for assignment confirmation.
  • Collect data at 298 K and 310 K to resolve overlapping peaks.

• Data Processing & Analysis:

  • Process all spectra using software (e.g., NMRPipe, TopSpin). Apply appropriate window functions and zero-filling.
  • Assign all ¹H and ¹³C resonances manually using iterative analysis of TOCSY, NOESY, and HSQC spectra.
  • Extract peak lists from NOESY spectra for distance restraints.

• Structure Calculation & Validation:

  • Input assigned chemical shifts and NOE-derived distance restraints into a calculation program (e.g., CYANA, XPLOR-NIH).
  • Perform simulated annealing to generate an ensemble of structures (e.g., 100).
  • Select the 20 lowest-energy structures. Superimpose them over the structured region (typically backbone atoms) to assess convergence.
  • Validate structures using RAMPAGE or PROCHECK-NMR. Deposit final ensemble in the Protein Data Bank (PDB).

Protocol 2: X-ray Crystallography of a RiPP Core Variant in Complex with a Binding Protein

Objective: To determine the crystal structure of a 4 kDa RiPP core variant (Mutant B) bound to its cognate transporter protein (45 kDa) at high resolution.

Materials: See "Research Reagent Solutions" below.

Procedure:

• Complex Preparation & Crystallization:
  • Co-express or individually express and purify the core variant and the transporter protein. Mix at a 1.2:1.0 molar ratio (peptide:protein) and incubate on ice for 1 hour.
  • Purify the complex using size-exclusion chromatography (SEC) in crystallization buffer (e.g., 10 mM HEPES pH 7.5, 50 mM NaCl).
  • Concentrate the complex to 10-15 mg/mL.
  • Set up crystallization trials using commercial sparse-matrix screens (e.g., Hampton Research Index, JCSG+) via sitting-drop vapor diffusion at 293 K. Mix 0.2 µL protein + 0.2 µL reservoir solution.

• Crystal Harvesting & Cryo-cooling:

  • Observe plates regularly. Once crystals appear (2-7 days), optimize conditions via grid screens.
  • Harvest a single crystal using a nylon loop. Cryo-cool by plunging into liquid nitrogen after brief soaking in reservoir solution supplemented with 20-25% glycerol or ethylene glycol as cryoprotectant.

• Data Collection & Processing:

  • Ship or transport cryo-cooled crystals to a synchrotron beamline.
  • Collect a complete X-ray diffraction dataset (360° rotation, 0.1-0.2° oscillation) at 100 K. Aim for resolution better than 2.0 Å.
  • Process the dataset: index, integrate, and scale using software like XDS, autoPROC, or HKL-3000.

• Structure Solution & Refinement:

  • Determine phases by molecular replacement (MR) using the apo-transporter structure (PDB: XXXX) as a search model in Phaser.
  • Build the bound core variant peptide into the clear difference electron density (Fo-Fc map) using Coot.
  • Perform iterative cycles of model refinement in Phenix.refine or REFMAC5 and manual rebuilding in Coot.
  • Validate the final model with MolProbity. Deposit the structure in the PDB.

Diagrams

Title: Decision Workflow for RiPP Structure Technique

Title: NMR Structure Determination Protocol Steps

Title: X-ray Crystallography Protocol Steps

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Structural Elucidation of RiPP Core Variants

Item	Function in Protocol	Example Product/Kit
Size-Exclusion Chromatography (SEC) Column	Final polishing step to purify peptide, protein, or complex in native buffer; removes aggregates.	Cytiva HiLoad 16/600 Superdex 75 pg (for proteins < 70 kDa).
NMR Shigemi Tube	Allows for high-quality NMR data acquisition with reduced sample volume (~200 µL of 1 mM sample).	Shigemi Inc. NMR Microtube (BMS-005B for 5 mm probes).
Cryoprobe-equipped NMR Spectrometer	Dramatically increases sensitivity (≥4x), enabling study of lower-concentration samples or shorter acquisition times.	Bruker Avance NEO with TCI Cryoprobe.
Crystallization Sparse-Matrix Screen Kits	Provides a broad, unbiased sampling of crystallization chemical space to identify initial hits.	Hampton Research Index or Molecular Dimensions JCSG+ screen.
Crystal Mounting Loops	Thin, flexible loops for harvesting fragile protein crystals from drops with minimal damage.	MiTeGen MicroLoops (various sizes).
Synchrotron Beamline Access	Source of high-intensity, tunable X-rays enabling rapid data collection from micro-crystals.	APS (Argonne), ESRF (Grenoble), or DESY (PETRA III).
Molecular Replacement Search Model	A previously solved, structurally homologous protein model required for phasing X-ray data.	AlphaFold2 Predicted Structure or related PDB entry.
Structure Refinement & Validation Software	Integrated suites for iterative model building, refinement against data, and geometric validation.	PHENIX suite and Coot molecular graphics.

Benchmarking Engineered RiPPs Against Natural Products and Existing Therapeutics

Application Notes

Within the broader thesis on RiPP precursor peptide core region diversification, this document provides protocols for benchmarking newly engineered Ribosomally synthesized and Post-translationally modified Peptides (RiPPs) against canonical natural products and approved therapeutics. The objective is to quantitatively assess improvements in target affinity, selectivity, stability, and in vitro efficacy.

Quantitative benchmarks are essential for evaluating engineered RiPPs. The following table consolidates target metrics from recent literature.

Table 1: Key Benchmarking Parameters for Engineered RiPPs

Parameter	Natural Product (e.g., Nisin)	Approved Therapeutic (e.g., Daptomycin)	Target for Engineered RiPPs	Measurement Method
Antimicrobial MIC (µg/mL)	0.5 - 32 (vs. Gram+)	0.12 - 8 (vs. Gram+)	≤ 0.5 (vs. target pathogens)	Broth microdilution (CLSI)
Serum Half-life (hrs)	~0.5 (Nisin)	8-9 (Daptomycin, human)	> 6	HPLC-MS of serum samples
Protease Resistance (t½, min)	Low (trypsin digestion)	High	> 120 min in trypsin	Fluorescent substrate assay
Target Affinity (Kd, nM)	10-100 (e.g., Lipid II)	1-10 (target dependent)	< 10	Surface Plasmon Resonance
Cytotoxicity (CC50, µM)	>100 (selective toxicity)	>100	>100 (therapeutic index >100)	MTT assay on HEK293 cells
Solubility (mg/mL)	Variable, often low	Formulation dependent	> 1 in aqueous buffer	Nephelometry

Research Reagent Solutions Toolkit

Table 2: Essential Reagents for RiPP Benchmarking Studies

Item	Function & Rationale
HEK293T Cell Line	Standard mammalian cell line for cytotoxicity (CC50) assessment.
Cation-Adjusted Mueller Hinton II Broth	Standardized medium for antimicrobial susceptibility testing (MIC).
Recombinant Target Protein (e.g., Sortase A)	Purified enzyme for binding affinity (Kd) studies via SPR or ITC.
Porcine Trypsin	Standard protease for evaluating peptide stability in digestive fluids.
SPR Chip (e.g., CMS, SA)	Sensor chip for real-time, label-free measurement of binding kinetics.
Stable Isotope-labeled Amino Acids	For metabolic labeling in RiPP production and tracking via LC-MS.
Human Serum (Pooled, Type AB)	For evaluating stability and half-life under physiologically relevant conditions.
LC-MS/MS System (Q-TOF preferred)	For precise characterization of RiPP modifications, purity, and stability.

Protocols

Protocol 1: Determining Minimum Inhibitory Concentration (MIC) Against ESKAPE Pathogens

Objective: To compare the antimicrobial potency of an engineered RiPP against reference compounds.

• Prepare a 1 mg/mL stock solution of the engineered RiPP in sterile 0.01% acetic acid with 0.2% BSA.
• Using cation-adjusted Mueller Hinton II broth, perform a 2-fold serial dilution of the RiPP in a 96-well microtiter plate (100 µL final volume/well).
• Inoculate each well with 5 x 10⁵ CFU/mL of a standardized bacterial suspension (e.g., Staphylococcus aureus).
• Include controls: growth (no compound), sterility (no inoculum), and reference antibiotics (e.g., daptomycin, vancomycin).
• Incubate at 37°C for 18-24 hours.
• The MIC is the lowest concentration that completely inhibits visible growth. Perform in triplicate.

Protocol 2: Serum Stability and Half-life Assay

Objective: To measure the degradation kinetics of an engineered RiPP in human serum.

• Dilute the purified RiPP to 100 µg/mL in 500 µL of pooled human serum. Incubate at 37°C.
• At time points (0, 0.5, 1, 2, 4, 8, 24 hrs), remove 50 µL aliquots.
• Immediately mix aliquots with 150 µL of ice-cold acetonitrile to precipitate serum proteins. Vortex and centrifuge at 14,000 x g for 10 min.
• Analyze the supernatant by RP-HPLC or LC-MS to quantify intact RiPP.
• Plot % intact RiPP vs. time. Calculate half-life (t½) using a first-order decay model.

Protocol 3: Binding Affinity via Surface Plasmon Resonance (SPR)

Objective: To determine the kinetic parameters (Ka, Kd, KD) of RiPP-target interaction.

• Immobilize the purified target protein (e.g., bacterial receptor) on a CMS sensor chip via amine coupling to a density of 2000-5000 RU.
• Using HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7.4) as running buffer, inject a 2-fold dilution series of the RiPP (e.g., 1.56 to 100 nM) at 30 µL/min for 120s association time, followed by 300s dissociation.
• Regenerate the chip surface with a 30s pulse of 10 mM glycine-HCl, pH 2.0.
• Process and double-reference (reference flow cell & blank injection) the sensorgrams.
• Fit the data to a 1:1 Langmuir binding model using the SPR instrument software to derive association (ka) and dissociation (kd) rate constants. Calculate equilibrium dissociation constant KD = kd/ka.

Visualizations

Diagram 1: Engineered RiPP benchmarking workflow.

Diagram 2: Decision pipeline for RiPP lead selection.

Diagram 3: SPR protocol for binding kinetics.

Assessing Pharmacokinetic and Selectivity Profiles Early in the Development Pipeline

Application Notes

Within RiPP (Ribosomally synthesized and post-translationally modified peptide) drug discovery, diversification of the precursor peptide core region is a central strategy to generate novel analogs with optimized bioactivity. This thesis posits that early-stage, parallel assessment of pharmacokinetic (PK) and pharmacodynamic (PD) selectivity is critical for prioritizing lead candidates from these diversified libraries. Relying solely on in vitro potency can yield compounds with poor developability or off-target toxicity. The following protocols outline integrated methodologies to evaluate key ADME (Absorption, Distribution, Metabolism, Excretion) properties and target selectivity concurrently with primary activity screening, accelerating the identification of viable RiPP-derived therapeutics.

Key Data Metrics for Early Triage

Early-stage profiling focuses on high-throughput predictive assays. Data should be aggregated for direct comparison, as shown in Table 1.

Table 1: Key Early-Development PK and Selectivity Parameters for RiPP Analogs

Parameter	Assay System	Target Value/Profile	Rationale for RiPP Development
Metabolic Stability	Microsomal/Hepatocyte Half-life (Human/Rodent)	t₁/₂ > 15 min (microsomes)	Predicts in vivo clearance; RiPPs often exhibit protease susceptibility.
Membrane Permeability	PAMPA, Caco-2 Apparent Permeability (Papp)	Papp > 1 x 10⁻⁶ cm/s (Caco-2)	Indicates potential for oral absorption or intracellular target engagement.
Plasma Protein Binding (PPB)	Equilibrium Dialysis, Ultrafiltration	% Unbound > 1-5%	High PPB can reduce free, active drug concentration and volume of distribution.
hERG Inhibition	Patch-clamp or binding assay (IC₅₀)	IC₅₀ > 10 µM	Early indicator of cardiac liability; critical for peptide ion channel interactions.
Off-Target Panel	Binding/Functional assays vs. GPCRs, Kinases, etc.	< 50% inhibition at 10 µM	Assesses selectivity; prevents progression of promiscuous RiPP scaffolds.
Cytotoxicity	HepG2 or HEK293 cell viability (CC₅₀)	CC₅₀ / EC₅₀ > 100	Establishes preliminary therapeutic index against common cell lines.

---

Experimental Protocols

Protocol 1: High-Throughput Metabolic Stability Assay Using Liver Microsomes

Objective: To determine the in vitro half-life (t₁/₂) and intrinsic clearance (CLint) of diversified RiPP core analogs. Reagents: Test RiPP compounds (10 mM in DMSO), Human/Rat liver microsomes (0.5 mg/mL), NADPH regeneration system, Phosphate buffer (0.1 M, pH 7.4), Acetonitrile (with internal standard). Procedure:

• Incubation: Pre-warm microsomal suspension and NADPH system. In a 96-well plate, mix 25 µL microsomes, 5 µL RiPP compound (1 µM final), and 65 µL buffer. Pre-incubate for 5 min at 37°C.
• Reaction Initiation: Start reaction by adding 5 µL NADPH system. For controls, use heat-inactivated microsomes or omit NADPH.
• Time Course Sampling: At t = 0, 5, 15, 30, and 60 minutes, remove 20 µL aliquots and quench in 80 µL ice-cold acetonitrile.
• Analysis: Centrifuge quenched samples (4000xg, 15 min). Analyze supernatant via LC-MS/MS to quantify remaining parent RiPP compound.
• Calculation: Plot Ln(% remaining) vs. time. Calculate slope (k) and t₁/₂ = 0.693/k. Determine CLint = (0.693 / t₁/₂) * (incubation volume / microsomal protein).

Protocol 2: Parallel Selectivity Screening via a Focused Off-Target Panel

Objective: To identify potential off-target interactions of lead RiPP analogs against a curated panel of safety-related targets. Reagents: RiPP compounds, Selectivity panel membranes (e.g., hERG, 5-HT2B, CYP2D6, etc.), Appropriate radioligands or fluorescent probes, Assay buffer, Scintillation fluid or detection reagents. Procedure:

• Assay Setup: In 96-well assay plates, add 20 µL of buffer containing the target membrane preparation.
• Compound Addition: Add 10 µL of RiPP compound at a final concentration of 10 µM (single-point screen) or a serial dilution for IC₅₀ determination.
• Ligand Addition: Add 20 µL of the appropriate radioligand/fluorophore at its Kd concentration. Include controls for total binding (no competitor) and nonspecific binding (with reference inhibitor).
• Incubation: Incubate according to specific target protocol (typically 60-120 min at room temp).
• Detection: Terminate reaction per kit instructions (e.g., filtration and washing for binding assays). Quantify bound ligand.
• Data Analysis: Calculate % inhibition = 100 * [1 - (Sample - Nonspecific)/(Total - Nonspecific)]. Prioritize compounds with <50% inhibition at 10 µM across the panel.

---

Visualizations

Title: Early-Stage RiPP Candidate Screening Workflow

Title: PK and Selectivity Pathways for RiPP Analogs

---

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in PK/Selectivity Profiling
Pooled Human Liver Microsomes (HLM)	Enzyme source for high-throughput metabolic stability assays; predicts Phase I clearance.
PAMPA (Parallel Artificial Membrane Permeability Assay) Plates	Non-cell-based system for rapid assessment of passive transcellular permeability.
hERG-Expressing Cell Line (e.g., CHO-hERG)	Essential for functional patch-clamp or fluorescence-based assays to evaluate cardiac risk.
Equilibrium Dialysis Devices (96-well format)	Gold-standard method for accurate determination of plasma protein binding (% unbound).
CYP450 Isozyme Inhibition Assay Kits (CYP3A4, 2D6, etc.)	Screen for potential drug-drug interaction liabilities due to CYP inhibition.
Safety Panel Membrane Preparations (from PerkinElmer, Eurofins)	Off-the-shelf panels for binding assays against key anti-targets (GPCRs, kinases, ion channels).
LC-MS/MS System with UHPLC	Core analytical platform for quantifying parent compound loss in stability assays and bioanalysis.
Stable, Isotopically Labeled Internal Standards	Critical for accurate and reproducible quantitation of RiPP peptides in complex matrices.

Conclusion

Diversification of the RiPP precursor core region represents a powerful, genetically encodable strategy to access novel bioactive compounds. Success hinges on integrating foundational knowledge of RiPP enzymology with advanced methodological toolkits for library creation, while systematically troubleshooting expression and modification hurdles. As validation techniques become more high-throughput and predictive models more accurate, the iterative design-build-test-learn cycle will accelerate. The future of RiPP engineering lies in seamlessly combining rational design with expansive combinatorial libraries, ultimately unlocking a vast, tunable chemical space for next-generation antibiotics, anti-cancer agents, and other therapeutics, directly addressing the urgent need for novel bioactive scaffolds in clinical development.